Efficacy and Safety of Subcutaneous Secukinumab (AIN457) for Moderate to Severe Chronic Plaque-type Psoriasis Assessing Different Doses and Dose Regimens

A Randomized, Double-blind, Multicenter Study of Subcutaneous Secukinumab, Assessing Psoriasis Area and Severity Index (PASI) Response and Maintenance of Response in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis on Either a Fixed Dose Regimen or on a Retreatment at Start of Relapse Regimen

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01406938

Acronym

SCULPTURE

Enrollment

967

Registered

2011-08-01

Start date

2011-08-31

Completion date

2013-05-31

Last updated

2015-05-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Moderate to Severe Plaque-type Psoriasis

Keywords

Psoriasis, plaque, inflammatory skin disease, scaly patches, AIN457, secukinumab, Moderate to Severe Plaque-type Psoriasis

Brief summary

This study will assess the safety and efficacy of two different doses and two different dose regimens of subcutaneous secukinumab in patients that have moderate to severe, chronic, plaque-type psoriasis.

Interventions

DRUGAIN457 150mg

(1 injection per dose) and placebo to secukinumab 150 mg

DRUGAIN457 300mg

secukinumab 150 mg (2 injections per dose)

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Moderate and severe plaque-type psoriasis diagnosed for at least 6 months. Severity of disease meeting all of the following three criteria: * PASI score of 12 or greater, * Investigator's Global Assessment (IGA) score of 3 or greater * Total body surface area (BSA) affected of 10% or greater. * Inadequate control by prior use of topical treatment, phototherapy and/or systemic therapy.

Exclusion criteria

* Current forms of psoriasis other than chronic plaque-type psoriasis (for example, pustular, erythrodermic, guttate). * Current drug-induced psoriasis. * Previous use of secukinumab or any drug that targets IL-17 or IL-17 receptor. * Significant medical problems such as uncontrolled hypertension, congestive heart failure or a condition that significantly immunocompromises the subject. * Hematological abnormalities. * History of an ongoing, chronic or recurrent infectious disease, or evidence of untreated tuberculosis. * History of lymphoproliferative disease or history of malignancy of any organ system within the past 5 years. * Pregnant or nursing (lactating) women. * Other protocol-defined inclusion/

Design outcomes

Primary

Measure	Time frame	Description
For the Fixed Interval Group and the Start of Relapse (SoR) Group, the Percentage of Participants (Who Responded to Treatment at Week 12) Maintaining a 75% Improvement From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 52	Week 40 , week 52	PASI: Combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section(head: 0.1, arms: 0.2 body: 0.3 legs: 0.4)

Secondary

Measure	Time frame	Description
Absolute Change From Baseline for PASI 50 / 75 / 90 / 100 and IGA 2011 Score of 0 or 1 at Week at Week 16, 20, 24,28,32,36,40,44,48,and Week 52	Baseline, week 12,16,20,24,28,32,36,40,44,48 and week 52	PASI: Combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section(head:01, arms:0.2 body:0.3 legs:0.4)
Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Induction)	Baseline, week 2, 4, 6, 8, 12	PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4). PASI 50, 75, 90 and 100 were defined as participants achieving ≥ 50%, 75%, 90% or 100% improvement from baseline. The IGA mod 2011 scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate and 4 = severe
Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Baseline, week 16,20,24,28,32,36,40,44,48, and Week 52	The IGA mod 2011 is a static scale, i.e., it refers exclusively to the participant's disease state at the time of the assessments and does not attempt a comparison to any of the participant's previous disease states at prior visits. The score ranges from 0 (clear) to 4 (severe. The score 0 is clear, 1 is almost clear, 2 is mild, 3 is moderate, and 4 is severe
Change From Baseline in EQ-5D at Each Visit, up to Week 52, (Induction)	Baseline to week 2, 4, 8, 12	ED-5Q: Participant rated questionnaire to assess health related quality of life in terms of a single utility score. Five domains are assessed mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) each with three possible score: 1 indicates no problems, better state of health; 3 indicates worst state of health (example confined to bed) A visual analog scale (VAS) assesses the health status from 0 (worst possible health state) to 100 (best possible health state)
Change From Baseline in EQ-5D at Each Visit, up to Week 52, (Maintenance)	Baseline to week 16, 20, 24, 28, 32, 36, 40, 44, 48, and Week 52.	ED-5Q: Participant rated questionnaire to assess health related quality of life in terms of a single utility score. Five domains are assessed mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) each with three possible score: 1 indicates no problems, better state of health; 3 indicates worst state of health (example confined to bed) A visual analog scale (VAS) assesses the health status from 0 (worst possible health state) to 100 (best possible health state)
Change From Baseline in Dermatology Life Quality Index (DLQI) Score. up to Week 52, (Induction)	Baseline to week 2, 4, 8, 12	The DLQI is a quality of life measure used in the psoriatic The 10-item questionnaire has a score range of 0 (best) to 30 (worst) with higher scores indicating poor quality of life. The instrument contains six functional scales (i.e., symptoms and feeling, daily activities, leisure, work and school, personal relationships, treatment). Each item has 4 response categories, ranging from 0 (not at all) to 3 (very much). Not relevant is also a valid response and is scored as 0. The DLQI total score is a sum of the 10 questions
Change From Baseline in Dermatology Life Quality Index (DLQI) Score. up to Week 52, (Maintenance)	Baseline to week 16, 20, 24, 28, 32, 36, 40, 44, 48, and Week 52.	The DLQI is a quality of life measure used in the psoriatic The 10-item questionnaire has a score range of 0 (best) to 30 (worst) with higher scores indicating poor quality of life. The instrument contains six functional scales (i.e., symptoms and feeling, daily activities, leisure, work and school, personal relationships, treatment). Each item has 4 response categories, ranging from 0 (not at all) to 3 (very much). Not relevant is also a valid response and is scored as 0. The DLQI total score is a sum of the 10 questions
Absolute Change From Baseline for PASI 50 / 75 / 90 / 100 and IGA 2011 Score of 0 or 1 at Week 2, 4, 6, 8, 12	Baseline, week 2, 3 , 4, 8, 12	PASI: Combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section(head:01, arms:0.2 body:0.3 legs:0.4)
% of Participants Achieving a DLQI Score of 0 or 1 at Each Visit up to Week 52, (Maintenance).	Baseline to week 16, 20, 24, 28, 32, 36, 40, 44, 48, and Week 52	The DLQI is a quality of life measure used in the psoriatic The 10-item questionnaire has a score range of 0 (best) to 30 (worst) with higher scores indicating poor quality of life. The instrument contains six functional scales (i.e., symptoms and feeling, daily activities, leisure, work and school, personal relationships, treatment). Each item has 4 response categories, ranging from 0 (not at all) to 3 (very much). Not relevant is also a valid response and is scored as 0. The DLQI total score is a sum of the 10 questions
Median Time to Relapse (Weeks) From Week 12.	Week 12 to week 16, 20, 24, 28, 32, 36, 40, 44, 48, and Week 52.	Median time to relapse (weeks) from week 12. Relapse is defined as greater than 50% loss of the maximal PASI improvement from baseline. PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4). A negative mean percentage change indicates improvement
Percent of Responders With PASI Equal to or Greater Than 50, PASI 75, PASI 90, PASI 100 and Percent of Responders With IGA Score of 0 or 1 Who Failed to Respond to a Previous Biologic Psoriasis Therapy	Week 12	PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4). PASI 50, 75, 90 and 100 were defined as participants achieving ≥ 50%, 75%, 90% or 100% improvement from baseline. The IGA mod 2011 scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate and 4 = severe.
Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	Week 16, 20, 24,28,32,36,40,44,48,and Week 52	PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4). PASI 50, 75, 90 and 100 were defined as participants achieving ≥ 50%, 75%, 90% or 100% improvement from baseline. The IGA mod 2011 scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate and 4 = severe.
Number of Secukinumab Injections Needed to Regain PASI 75 Response From Start of Relapse After Week 12	week 16, 20, 24,28,32,36,40,44,48,and Week 52	The number of secukinumab injections needed for participants to regain PASI 75 response from the start of relapse after week 12
Number of Participants Developing Anti-secukinumab Antibodies	Baseline, weeks 12, 24, 52 and 60	The development of anti-secunimubab anti-bodies will decrease a participant's ability to respond to secukinumab treatment. The number of participants developing anti-secukinumab anti-bodies was measured from Baseline to week 12, 24, 52 and 8 weeks after treatment at week 60
% of Participants Achieving a DLQI Score of 0 or 1 at Each Visit up to Week 52, (Induction)	Baseline to week 2, 4, 6, 8, 12	The DLQI is a quality of life measure used in the psoriatic The 10-item questionnaire has a score range of 0 (best) to 30 (worst) with higher scores indicating poor quality of life. The instrument contains six functional scales (i.e., symptoms and feeling, daily activities, leisure, work and school, personal relationships, treatment). Each item has 4 response categories, ranging from 0 (not at all) to 3 (very much). Not relevant is also a valid response and is scored as 0. The DLQI total score is a sum of the 10 questions

Countries

Austria, Bulgaria, Canada, Czechia, France, Germany, India, Italy, Japan, Poland, Singapore, Slovakia, Switzerland, United Kingdom, United States, Vietnam

Participant flow

Recruitment details

966 patients randomized to two groups, induction secukinumab 150 mg or secukinumab 300 mg. Most randomized patients, 928/966 completed the 12-week induction period. 928 completed the induction period, a total of 843 were re-randomized to the maintenance period to either fixed interval dosing or start of relapse dosing at their respective dose level

Participants by arm

Arm	Count
AIN457150 mg- Induction Period Only(IPO) secukinumab 150 mg (1 injection per dose) and placebo to secukinumab 150 mg (1 injection per dose). Induction period only (IPO)	482
AIN457 300 mg - IPO secukinumab- 2 x 150mg injections per dose	484
Total	966

Withdrawals & dropouts

Period	Reason	FG000	FG001	FG002	FG003	FG004	FG005
Follow up	Lack of Efficacy	3	2	1	0	0	0
Follow up	Lost to Follow-up	1	1	0	1	2	1
Follow up	Patient/guardian decision	4	2	4	2	4	1
Follow up	Physician Decision	0	0	2	0	3	1
Follow up	Protocol Violation	0	0	1	0	0	0
Induction Period	Adverse Event	8	9	0	0	0	0
Induction Period	Lack of Efficacy	1	0	0	0	0	0
Induction Period	Lost to Follow-up	2	3	0	0	0	0
Induction Period	Protocol deviation	1	0	0	0	0	0
Induction Period	Subject/guardian decision	6	8	0	0	0	0
Maintenance Period	Adverse Event	0	0	2	8	4	2
Maintenance Period	Death	0	0	0	0	1	0
Maintenance Period	Lack of Efficacy	0	0	2	1	3	5
Maintenance Period	Lost to Follow-up	0	0	0	0	4	0
Maintenance Period	Pregnancy	0	0	0	0	1	0
Maintenance Period	Protocol Violation	0	0	2	2	2	2
Maintenance Period	Subject/guardian decision	0	0	11	7	10	7

Baseline characteristics

Characteristic	AIN457150 mg- Induction Period Only(IPO)	AIN457 300 mg - IPO	Total
Age, Continuous	45.3 Years STANDARD_DEVIATION 12.83	46.7 Years STANDARD_DEVIATION 12.83	46.0 Years STANDARD_DEVIATION 12.84
Sex: Female, Male Female	177 Participants	151 Participants	328 Participants
Sex: Female, Male Male	305 Participants	333 Participants	638 Participants

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk	EG002 affected / at risk	EG003 affected / at risk	EG004 affected / at risk	EG005 affected / at risk	EG006 affected / at risk	EG007 affected / at risk	EG008 affected / at risk	EG009 affected / at risk	EG010 affected / at risk	EG011 affected / at risk
deaths Total, all-cause mortality	— / —	— / —	— / —	— / —	— / —	— / —	— / —	— / —	— / —	— / —	— / —	— / —
other Total, other adverse events	190 / 482	178 / 484	134 / 203	137 / 217	120 / 205	126 / 217	6 / 27	6 / 23	8 / 40	7 / 39	13 / 39	9 / 35
serious Total, serious adverse events	8 / 482	10 / 484	12 / 203	18 / 217	12 / 205	14 / 217	1 / 27	0 / 23	2 / 40	1 / 39	1 / 39	0 / 35

Outcome results

Primary

For the Fixed Interval Group and the Start of Relapse (SoR) Group, the Percentage of Participants (Who Responded to Treatment at Week 12) Maintaining a 75% Improvement From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 52

PASI: Combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section(head: 0.1, arms: 0.2 body: 0.3 legs: 0.4)

Time frame: Week 40 , week 52

Population: Full analysis set (FAS) - All patients to whom study treatment was assigned.

Arm	Measure	Value (NUMBER)
AIN457 150 mg - Fixed Interval (FI)	For the Fixed Interval Group and the Start of Relapse (SoR) Group, the Percentage of Participants (Who Responded to Treatment at Week 12) Maintaining a 75% Improvement From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 52	62.1 Percent of participants
AIN457 300 mg FI	For the Fixed Interval Group and the Start of Relapse (SoR) Group, the Percentage of Participants (Who Responded to Treatment at Week 12) Maintaining a 75% Improvement From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 52	78.2 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	For the Fixed Interval Group and the Start of Relapse (SoR) Group, the Percentage of Participants (Who Responded to Treatment at Week 12) Maintaining a 75% Improvement From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 52	52.4 Percent of participants
AIN457 300 mg- SoR	For the Fixed Interval Group and the Start of Relapse (SoR) Group, the Percentage of Participants (Who Responded to Treatment at Week 12) Maintaining a 75% Improvement From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 52	67.7 Percent of participants

Secondary

Absolute Change From Baseline for PASI 50 / 75 / 90 / 100 and IGA 2011 Score of 0 or 1 at Week 2, 4, 6, 8, 12

Time frame: Baseline, week 2, 3 , 4, 8, 12

Population: Full analysis set (FAS) - All patients to whom study treatment was assigned

Arm	Measure	Group	Value (MEAN)	Dispersion
AIN457150 mg- Induction Period Only(IPO)	Absolute Change From Baseline for PASI 50 / 75 / 90 / 100 and IGA 2011 Score of 0 or 1 at Week 2, 4, 6, 8, 12	Week 12	-20.71 Units on a scale	Standard Deviation 10.804
AIN457150 mg- Induction Period Only(IPO)	Absolute Change From Baseline for PASI 50 / 75 / 90 / 100 and IGA 2011 Score of 0 or 1 at Week 2, 4, 6, 8, 12	Week 3	-11.13 Units on a scale	Standard Deviation 7.826
AIN457150 mg- Induction Period Only(IPO)	Absolute Change From Baseline for PASI 50 / 75 / 90 / 100 and IGA 2011 Score of 0 or 1 at Week 2, 4, 6, 8, 12	Week 4	-14.18 Units on a scale	Standard Deviation 8.956
AIN457150 mg- Induction Period Only(IPO)	Absolute Change From Baseline for PASI 50 / 75 / 90 / 100 and IGA 2011 Score of 0 or 1 at Week 2, 4, 6, 8, 12	Week 8	-18.69 Units on a scale	Standard Deviation 10.147
AIN457150 mg- Induction Period Only(IPO)	Absolute Change From Baseline for PASI 50 / 75 / 90 / 100 and IGA 2011 Score of 0 or 1 at Week 2, 4, 6, 8, 12	Week 2	-7.46 Units on a scale	Standard Deviation 6.338
AIN457 300 mg - IPO	Absolute Change From Baseline for PASI 50 / 75 / 90 / 100 and IGA 2011 Score of 0 or 1 at Week 2, 4, 6, 8, 12	Week 8	-19.56 Units on a scale	Standard Deviation 9.356
AIN457 300 mg - IPO	Absolute Change From Baseline for PASI 50 / 75 / 90 / 100 and IGA 2011 Score of 0 or 1 at Week 2, 4, 6, 8, 12	Week 3	-12.97 Units on a scale	Standard Deviation 7.826
AIN457 300 mg - IPO	Absolute Change From Baseline for PASI 50 / 75 / 90 / 100 and IGA 2011 Score of 0 or 1 at Week 2, 4, 6, 8, 12	Week 4	-15.90 Units on a scale	Standard Deviation 8.838
AIN457 300 mg - IPO	Absolute Change From Baseline for PASI 50 / 75 / 90 / 100 and IGA 2011 Score of 0 or 1 at Week 2, 4, 6, 8, 12	Week 12	-20.89 Units on a scale	Standard Deviation 9.584
AIN457 300 mg - IPO	Absolute Change From Baseline for PASI 50 / 75 / 90 / 100 and IGA 2011 Score of 0 or 1 at Week 2, 4, 6, 8, 12	Week 2	-9.28 Units on a scale	Standard Deviation 6.752

Secondary

Absolute Change From Baseline for PASI 50 / 75 / 90 / 100 and IGA 2011 Score of 0 or 1 at Week at Week 16, 20, 24,28,32,36,40,44,48,and Week 52

Time frame: Baseline, week 12,16,20,24,28,32,36,40,44,48 and week 52

Population: Full analysis set (FAS) - All patients to whom study treatment was assigned

Arm	Measure	Group	Value (MEAN)	Dispersion
AIN457 150 mg - Fixed Interval (FI)	Absolute Change From Baseline for PASI 50 / 75 / 90 / 100 and IGA 2011 Score of 0 or 1 at Week at Week 16, 20, 24,28,32,36,40,44,48,and Week 52	Week 36	-19.82 Units on a scale	Standard Deviation 9.908
AIN457 150 mg - Fixed Interval (FI)	Absolute Change From Baseline for PASI 50 / 75 / 90 / 100 and IGA 2011 Score of 0 or 1 at Week at Week 16, 20, 24,28,32,36,40,44,48,and Week 52	Week 28	-20.29 Units on a scale	Standard Deviation 9.73
AIN457 150 mg - Fixed Interval (FI)	Absolute Change From Baseline for PASI 50 / 75 / 90 / 100 and IGA 2011 Score of 0 or 1 at Week at Week 16, 20, 24,28,32,36,40,44,48,and Week 52	Week 52	-18.79 Units on a scale	Standard Deviation 9.904
AIN457 150 mg - Fixed Interval (FI)	Absolute Change From Baseline for PASI 50 / 75 / 90 / 100 and IGA 2011 Score of 0 or 1 at Week at Week 16, 20, 24,28,32,36,40,44,48,and Week 52	Week 32	-20.11 Units on a scale	Standard Deviation 9.847
AIN457 150 mg - Fixed Interval (FI)	Absolute Change From Baseline for PASI 50 / 75 / 90 / 100 and IGA 2011 Score of 0 or 1 at Week at Week 16, 20, 24,28,32,36,40,44,48,and Week 52	Week 20	-20.79 Units on a scale	Standard Deviation 9.739
AIN457 150 mg - Fixed Interval (FI)	Absolute Change From Baseline for PASI 50 / 75 / 90 / 100 and IGA 2011 Score of 0 or 1 at Week at Week 16, 20, 24,28,32,36,40,44,48,and Week 52	Week 12	-21.52 Units on a scale	Standard Deviation 9.553
AIN457 150 mg - Fixed Interval (FI)	Absolute Change From Baseline for PASI 50 / 75 / 90 / 100 and IGA 2011 Score of 0 or 1 at Week at Week 16, 20, 24,28,32,36,40,44,48,and Week 52	Week 48	-19.04 Units on a scale	Standard Deviation 10.093
AIN457 150 mg - Fixed Interval (FI)	Absolute Change From Baseline for PASI 50 / 75 / 90 / 100 and IGA 2011 Score of 0 or 1 at Week at Week 16, 20, 24,28,32,36,40,44,48,and Week 52	Week 44	-19.40 Units on a scale	Standard Deviation 9.691
AIN457 150 mg - Fixed Interval (FI)	Absolute Change From Baseline for PASI 50 / 75 / 90 / 100 and IGA 2011 Score of 0 or 1 at Week at Week 16, 20, 24,28,32,36,40,44,48,and Week 52	Week 24	-20.61 Units on a scale	Standard Deviation 9.745
AIN457 150 mg - Fixed Interval (FI)	Absolute Change From Baseline for PASI 50 / 75 / 90 / 100 and IGA 2011 Score of 0 or 1 at Week at Week 16, 20, 24,28,32,36,40,44,48,and Week 52	Week 16	-21.23 Units on a scale	Standard Deviation 9.676
AIN457 150 mg - Fixed Interval (FI)	Absolute Change From Baseline for PASI 50 / 75 / 90 / 100 and IGA 2011 Score of 0 or 1 at Week at Week 16, 20, 24,28,32,36,40,44,48,and Week 52	Week 40	-19.51 Units on a scale	Standard Deviation 9.821
AIN457 300 mg FI	Absolute Change From Baseline for PASI 50 / 75 / 90 / 100 and IGA 2011 Score of 0 or 1 at Week at Week 16, 20, 24,28,32,36,40,44,48,and Week 52	Week 20	-22.47 Units on a scale	Standard Deviation 9.237
AIN457 300 mg FI	Absolute Change From Baseline for PASI 50 / 75 / 90 / 100 and IGA 2011 Score of 0 or 1 at Week at Week 16, 20, 24,28,32,36,40,44,48,and Week 52	Week 16	-22.61 Units on a scale	Standard Deviation 9.31
AIN457 300 mg FI	Absolute Change From Baseline for PASI 50 / 75 / 90 / 100 and IGA 2011 Score of 0 or 1 at Week at Week 16, 20, 24,28,32,36,40,44,48,and Week 52	Week 24	-22.30 Units on a scale	Standard Deviation 9.262
AIN457 300 mg FI	Absolute Change From Baseline for PASI 50 / 75 / 90 / 100 and IGA 2011 Score of 0 or 1 at Week at Week 16, 20, 24,28,32,36,40,44,48,and Week 52	Week 28	-22.13 Units on a scale	Standard Deviation 9.244
AIN457 300 mg FI	Absolute Change From Baseline for PASI 50 / 75 / 90 / 100 and IGA 2011 Score of 0 or 1 at Week at Week 16, 20, 24,28,32,36,40,44,48,and Week 52	Week 32	-21.98 Units on a scale	Standard Deviation 9.195
AIN457 300 mg FI	Absolute Change From Baseline for PASI 50 / 75 / 90 / 100 and IGA 2011 Score of 0 or 1 at Week at Week 16, 20, 24,28,32,36,40,44,48,and Week 52	Week 36	-21.79 Units on a scale	Standard Deviation 9.324
AIN457 300 mg FI	Absolute Change From Baseline for PASI 50 / 75 / 90 / 100 and IGA 2011 Score of 0 or 1 at Week at Week 16, 20, 24,28,32,36,40,44,48,and Week 52	Week 40	-21.71 Units on a scale	Standard Deviation 9.369
AIN457 300 mg FI	Absolute Change From Baseline for PASI 50 / 75 / 90 / 100 and IGA 2011 Score of 0 or 1 at Week at Week 16, 20, 24,28,32,36,40,44,48,and Week 52	Week 44	-21.58 Units on a scale	Standard Deviation 9.398
AIN457 300 mg FI	Absolute Change From Baseline for PASI 50 / 75 / 90 / 100 and IGA 2011 Score of 0 or 1 at Week at Week 16, 20, 24,28,32,36,40,44,48,and Week 52	Week 52	21.47 Units on a scale	Standard Deviation 9.402
AIN457 300 mg FI	Absolute Change From Baseline for PASI 50 / 75 / 90 / 100 and IGA 2011 Score of 0 or 1 at Week at Week 16, 20, 24,28,32,36,40,44,48,and Week 52	Week 12	-22.32 Units on a scale	Standard Deviation 8.943
AIN457 300 mg FI	Absolute Change From Baseline for PASI 50 / 75 / 90 / 100 and IGA 2011 Score of 0 or 1 at Week at Week 16, 20, 24,28,32,36,40,44,48,and Week 52	Week 48	-21.34 Units on a scale	Standard Deviation 9.681
AIN457 150 mg- Start of Relapse (SoR)	Absolute Change From Baseline for PASI 50 / 75 / 90 / 100 and IGA 2011 Score of 0 or 1 at Week at Week 16, 20, 24,28,32,36,40,44,48,and Week 52	Week 12	-23.19 Units on a scale	Standard Deviation 11.063
AIN457 150 mg- Start of Relapse (SoR)	Absolute Change From Baseline for PASI 50 / 75 / 90 / 100 and IGA 2011 Score of 0 or 1 at Week at Week 16, 20, 24,28,32,36,40,44,48,and Week 52	Week 40	-18.30 Units on a scale	Standard Deviation 10.66
AIN457 150 mg- Start of Relapse (SoR)	Absolute Change From Baseline for PASI 50 / 75 / 90 / 100 and IGA 2011 Score of 0 or 1 at Week at Week 16, 20, 24,28,32,36,40,44,48,and Week 52	Week 16	-23.26 Units on a scale	Standard Deviation 11.158
AIN457 150 mg- Start of Relapse (SoR)	Absolute Change From Baseline for PASI 50 / 75 / 90 / 100 and IGA 2011 Score of 0 or 1 at Week at Week 16, 20, 24,28,32,36,40,44,48,and Week 52	Week 52	-17.40 Units on a scale	Standard Deviation 10.719
AIN457 150 mg- Start of Relapse (SoR)	Absolute Change From Baseline for PASI 50 / 75 / 90 / 100 and IGA 2011 Score of 0 or 1 at Week at Week 16, 20, 24,28,32,36,40,44,48,and Week 52	Week 28	-20.53 Units on a scale	Standard Deviation 11.754
AIN457 150 mg- Start of Relapse (SoR)	Absolute Change From Baseline for PASI 50 / 75 / 90 / 100 and IGA 2011 Score of 0 or 1 at Week at Week 16, 20, 24,28,32,36,40,44,48,and Week 52	Week 44	-17.73 Units on a scale	Standard Deviation 11.041
AIN457 150 mg- Start of Relapse (SoR)	Absolute Change From Baseline for PASI 50 / 75 / 90 / 100 and IGA 2011 Score of 0 or 1 at Week at Week 16, 20, 24,28,32,36,40,44,48,and Week 52	Week 32	-19.41 Units on a scale	Standard Deviation 10.962
AIN457 150 mg- Start of Relapse (SoR)	Absolute Change From Baseline for PASI 50 / 75 / 90 / 100 and IGA 2011 Score of 0 or 1 at Week at Week 16, 20, 24,28,32,36,40,44,48,and Week 52	Week 24	-21.36 Units on a scale	Standard Deviation 11.938
AIN457 150 mg- Start of Relapse (SoR)	Absolute Change From Baseline for PASI 50 / 75 / 90 / 100 and IGA 2011 Score of 0 or 1 at Week at Week 16, 20, 24,28,32,36,40,44,48,and Week 52	Week 20	-22.28 Units on a scale	Standard Deviation 11.548
AIN457 150 mg- Start of Relapse (SoR)	Absolute Change From Baseline for PASI 50 / 75 / 90 / 100 and IGA 2011 Score of 0 or 1 at Week at Week 16, 20, 24,28,32,36,40,44,48,and Week 52	Week 48	-17.48 Units on a scale	Standard Deviation 10.638
AIN457 150 mg- Start of Relapse (SoR)	Absolute Change From Baseline for PASI 50 / 75 / 90 / 100 and IGA 2011 Score of 0 or 1 at Week at Week 16, 20, 24,28,32,36,40,44,48,and Week 52	Week 36	-18.86 Units on a scale	Standard Deviation 10.625
AIN457 300 mg- SoR	Absolute Change From Baseline for PASI 50 / 75 / 90 / 100 and IGA 2011 Score of 0 or 1 at Week at Week 16, 20, 24,28,32,36,40,44,48,and Week 52	Week 48	-16.58 Units on a scale	Standard Deviation 9.04
AIN457 300 mg- SoR	Absolute Change From Baseline for PASI 50 / 75 / 90 / 100 and IGA 2011 Score of 0 or 1 at Week at Week 16, 20, 24,28,32,36,40,44,48,and Week 52	Week 40	-17.89 Units on a scale	Standard Deviation 9.837
AIN457 300 mg- SoR	Absolute Change From Baseline for PASI 50 / 75 / 90 / 100 and IGA 2011 Score of 0 or 1 at Week at Week 16, 20, 24,28,32,36,40,44,48,and Week 52	Week 20	-20.97 Units on a scale	Standard Deviation 9.787
AIN457 300 mg- SoR	Absolute Change From Baseline for PASI 50 / 75 / 90 / 100 and IGA 2011 Score of 0 or 1 at Week at Week 16, 20, 24,28,32,36,40,44,48,and Week 52	Week 12	-21.58 Units on a scale	Standard Deviation 9.448
AIN457 300 mg- SoR	Absolute Change From Baseline for PASI 50 / 75 / 90 / 100 and IGA 2011 Score of 0 or 1 at Week at Week 16, 20, 24,28,32,36,40,44,48,and Week 52	Week 44	-17.03 Units on a scale	Standard Deviation 9.876
AIN457 300 mg- SoR	Absolute Change From Baseline for PASI 50 / 75 / 90 / 100 and IGA 2011 Score of 0 or 1 at Week at Week 16, 20, 24,28,32,36,40,44,48,and Week 52	Week 36	-18.14 Units on a scale	Standard Deviation 9.352
AIN457 300 mg- SoR	Absolute Change From Baseline for PASI 50 / 75 / 90 / 100 and IGA 2011 Score of 0 or 1 at Week at Week 16, 20, 24,28,32,36,40,44,48,and Week 52	Week 16	-21.58 Units on a scale	Standard Deviation 9.626
AIN457 300 mg- SoR	Absolute Change From Baseline for PASI 50 / 75 / 90 / 100 and IGA 2011 Score of 0 or 1 at Week at Week 16, 20, 24,28,32,36,40,44,48,and Week 52	Week 52	-16.33 Units on a scale	Standard Deviation 8.322
AIN457 300 mg- SoR	Absolute Change From Baseline for PASI 50 / 75 / 90 / 100 and IGA 2011 Score of 0 or 1 at Week at Week 16, 20, 24,28,32,36,40,44,48,and Week 52	Week 32	-18.68 Units on a scale	Standard Deviation 9.983
AIN457 300 mg- SoR	Absolute Change From Baseline for PASI 50 / 75 / 90 / 100 and IGA 2011 Score of 0 or 1 at Week at Week 16, 20, 24,28,32,36,40,44,48,and Week 52	Week 24	-20.09 Units on a scale	Standard Deviation 9.904
AIN457 300 mg- SoR	Absolute Change From Baseline for PASI 50 / 75 / 90 / 100 and IGA 2011 Score of 0 or 1 at Week at Week 16, 20, 24,28,32,36,40,44,48,and Week 52	Week 28	-19.27 Units on a scale	Standard Deviation 9.844

Secondary

Change From Baseline in Dermatology Life Quality Index (DLQI) Score. up to Week 52, (Induction)

The DLQI is a quality of life measure used in the psoriatic The 10-item questionnaire has a score range of 0 (best) to 30 (worst) with higher scores indicating poor quality of life. The instrument contains six functional scales (i.e., symptoms and feeling, daily activities, leisure, work and school, personal relationships, treatment). Each item has 4 response categories, ranging from 0 (not at all) to 3 (very much). Not relevant is also a valid response and is scored as 0. The DLQI total score is a sum of the 10 questions

Time frame: Baseline to week 2, 4, 8, 12

Population: Full analysis set (FAS) - All patients to whom study treatment was assigned

Arm	Measure	Group	Value (MEAN)	Dispersion
AIN457150 mg- Induction Period Only(IPO)	Change From Baseline in Dermatology Life Quality Index (DLQI) Score. up to Week 52, (Induction)	Week 8 DLQI total score	-10.2 Units on a scale	Standard Deviation 6.4
AIN457150 mg- Induction Period Only(IPO)	Change From Baseline in Dermatology Life Quality Index (DLQI) Score. up to Week 52, (Induction)	Week 2 DLQI total score	-5.5 Units on a scale	Standard Deviation 5.02
AIN457150 mg- Induction Period Only(IPO)	Change From Baseline in Dermatology Life Quality Index (DLQI) Score. up to Week 52, (Induction)	Week 12 DLQI total score	-10.8 Units on a scale	Standard Deviation 6.75
AIN457150 mg- Induction Period Only(IPO)	Change From Baseline in Dermatology Life Quality Index (DLQI) Score. up to Week 52, (Induction)	Week 4 DLQI total score	-8.2 Units on a scale	Standard Deviation 6.11
AIN457 300 mg - IPO	Change From Baseline in Dermatology Life Quality Index (DLQI) Score. up to Week 52, (Induction)	Week 12 DLQI total score	-11 Units on a scale	Standard Deviation 7.01
AIN457 300 mg - IPO	Change From Baseline in Dermatology Life Quality Index (DLQI) Score. up to Week 52, (Induction)	Week 4 DLQI total score	-8.7 Units on a scale	Standard Deviation 6.29
AIN457 300 mg - IPO	Change From Baseline in Dermatology Life Quality Index (DLQI) Score. up to Week 52, (Induction)	Week 8 DLQI total score	-10.3 Units on a scale	Standard Deviation 6.73
AIN457 300 mg - IPO	Change From Baseline in Dermatology Life Quality Index (DLQI) Score. up to Week 52, (Induction)	Week 2 DLQI total score	-6 Units on a scale	Standard Deviation 5.1

Secondary

Change From Baseline in Dermatology Life Quality Index (DLQI) Score. up to Week 52, (Maintenance)

Time frame: Baseline to week 16, 20, 24, 28, 32, 36, 40, 44, 48, and Week 52.

Population: Full analysis set (FAS) - All patients to whom study treatment was assigned

Arm	Measure	Group	Value (MEAN)	Dispersion
AIN457 150 mg - Fixed Interval (FI)	Change From Baseline in Dermatology Life Quality Index (DLQI) Score. up to Week 52, (Maintenance)	Week 16	-11 Units on a scale	Standard Deviation 6.63
AIN457 150 mg - Fixed Interval (FI)	Change From Baseline in Dermatology Life Quality Index (DLQI) Score. up to Week 52, (Maintenance)	Week 20	-10.6 Units on a scale	Standard Deviation 6.5
AIN457 150 mg - Fixed Interval (FI)	Change From Baseline in Dermatology Life Quality Index (DLQI) Score. up to Week 52, (Maintenance)	Week 24	-10.5 Units on a scale	Standard Deviation 6.67
AIN457 150 mg - Fixed Interval (FI)	Change From Baseline in Dermatology Life Quality Index (DLQI) Score. up to Week 52, (Maintenance)	Week 28	-10.5 Units on a scale	Standard Deviation 6.68
AIN457 150 mg - Fixed Interval (FI)	Change From Baseline in Dermatology Life Quality Index (DLQI) Score. up to Week 52, (Maintenance)	Week 32	-10.5 Units on a scale	Standard Deviation 6.76
AIN457 150 mg - Fixed Interval (FI)	Change From Baseline in Dermatology Life Quality Index (DLQI) Score. up to Week 52, (Maintenance)	Week 36	-10.2 Units on a scale	Standard Deviation 6.94
AIN457 150 mg - Fixed Interval (FI)	Change From Baseline in Dermatology Life Quality Index (DLQI) Score. up to Week 52, (Maintenance)	Week 40	-10.1 Units on a scale	Standard Deviation 6.83
AIN457 150 mg - Fixed Interval (FI)	Change From Baseline in Dermatology Life Quality Index (DLQI) Score. up to Week 52, (Maintenance)	Week 44	-10.2 Units on a scale	Standard Deviation 6.72
AIN457 150 mg - Fixed Interval (FI)	Change From Baseline in Dermatology Life Quality Index (DLQI) Score. up to Week 52, (Maintenance)	Week 48	-10 Units on a scale	Standard Deviation 6.57
AIN457 150 mg - Fixed Interval (FI)	Change From Baseline in Dermatology Life Quality Index (DLQI) Score. up to Week 52, (Maintenance)	Week 52	-9.8 Units on a scale	Standard Deviation 7.06
AIN457 300 mg FI	Change From Baseline in Dermatology Life Quality Index (DLQI) Score. up to Week 52, (Maintenance)	Week 24	-11.1 Units on a scale	Standard Deviation 7.39
AIN457 300 mg FI	Change From Baseline in Dermatology Life Quality Index (DLQI) Score. up to Week 52, (Maintenance)	Week 48	-10.8 Units on a scale	Standard Deviation 7.38
AIN457 300 mg FI	Change From Baseline in Dermatology Life Quality Index (DLQI) Score. up to Week 52, (Maintenance)	Week 28	-11 Units on a scale	Standard Deviation 7.22
AIN457 300 mg FI	Change From Baseline in Dermatology Life Quality Index (DLQI) Score. up to Week 52, (Maintenance)	Week 32	-10.9 Units on a scale	Standard Deviation 7.17
AIN457 300 mg FI	Change From Baseline in Dermatology Life Quality Index (DLQI) Score. up to Week 52, (Maintenance)	Week 36	-10.9 Units on a scale	Standard Deviation 7.3
AIN457 300 mg FI	Change From Baseline in Dermatology Life Quality Index (DLQI) Score. up to Week 52, (Maintenance)	Week 40	-10.8 Units on a scale	Standard Deviation 7.33
AIN457 300 mg FI	Change From Baseline in Dermatology Life Quality Index (DLQI) Score. up to Week 52, (Maintenance)	Week 52	-10.9 Units on a scale	Standard Deviation 7.31
AIN457 300 mg FI	Change From Baseline in Dermatology Life Quality Index (DLQI) Score. up to Week 52, (Maintenance)	Week 44	-10.8 Units on a scale	Standard Deviation 7.46
AIN457 300 mg FI	Change From Baseline in Dermatology Life Quality Index (DLQI) Score. up to Week 52, (Maintenance)	Week 16	-11.4 Units on a scale	Standard Deviation 7.12
AIN457 300 mg FI	Change From Baseline in Dermatology Life Quality Index (DLQI) Score. up to Week 52, (Maintenance)	Week 20	-11 Units on a scale	Standard Deviation 7.18
AIN457 150 mg- Start of Relapse (SoR)	Change From Baseline in Dermatology Life Quality Index (DLQI) Score. up to Week 52, (Maintenance)	Week 44	-8.4 Units on a scale	Standard Deviation 7.07
AIN457 150 mg- Start of Relapse (SoR)	Change From Baseline in Dermatology Life Quality Index (DLQI) Score. up to Week 52, (Maintenance)	Week 40	-8.4 Units on a scale	Standard Deviation 7.22
AIN457 150 mg- Start of Relapse (SoR)	Change From Baseline in Dermatology Life Quality Index (DLQI) Score. up to Week 52, (Maintenance)	Week 52	-8.4 Units on a scale	Standard Deviation 7.46
AIN457 150 mg- Start of Relapse (SoR)	Change From Baseline in Dermatology Life Quality Index (DLQI) Score. up to Week 52, (Maintenance)	Week 16	-11.4 Units on a scale	Standard Deviation 6.98
AIN457 150 mg- Start of Relapse (SoR)	Change From Baseline in Dermatology Life Quality Index (DLQI) Score. up to Week 52, (Maintenance)	Week 28	-9.7 Units on a scale	Standard Deviation 7.39
AIN457 150 mg- Start of Relapse (SoR)	Change From Baseline in Dermatology Life Quality Index (DLQI) Score. up to Week 52, (Maintenance)	Week 36	-8.6 Units on a scale	Standard Deviation 7.55
AIN457 150 mg- Start of Relapse (SoR)	Change From Baseline in Dermatology Life Quality Index (DLQI) Score. up to Week 52, (Maintenance)	Week 48	-8.6 Units on a scale	Standard Deviation 7.41
AIN457 150 mg- Start of Relapse (SoR)	Change From Baseline in Dermatology Life Quality Index (DLQI) Score. up to Week 52, (Maintenance)	Week 20	-10.6 Units on a scale	Standard Deviation 7.55
AIN457 150 mg- Start of Relapse (SoR)	Change From Baseline in Dermatology Life Quality Index (DLQI) Score. up to Week 52, (Maintenance)	Week 32	-8.6 Units on a scale	Standard Deviation 7.66
AIN457 150 mg- Start of Relapse (SoR)	Change From Baseline in Dermatology Life Quality Index (DLQI) Score. up to Week 52, (Maintenance)	Week 24	-10.1 Units on a scale	Standard Deviation 7.65
AIN457 300 mg- SoR	Change From Baseline in Dermatology Life Quality Index (DLQI) Score. up to Week 52, (Maintenance)	Week 32	-8.9 Units on a scale	Standard Deviation 7.61
AIN457 300 mg- SoR	Change From Baseline in Dermatology Life Quality Index (DLQI) Score. up to Week 52, (Maintenance)	Week 44	-8.6 Units on a scale	Standard Deviation 7.29
AIN457 300 mg- SoR	Change From Baseline in Dermatology Life Quality Index (DLQI) Score. up to Week 52, (Maintenance)	Week 36	-8.5 Units on a scale	Standard Deviation 7.79
AIN457 300 mg- SoR	Change From Baseline in Dermatology Life Quality Index (DLQI) Score. up to Week 52, (Maintenance)	Week 52	-7.6 Units on a scale	Standard Deviation 7.14
AIN457 300 mg- SoR	Change From Baseline in Dermatology Life Quality Index (DLQI) Score. up to Week 52, (Maintenance)	Week 40	-8.5 Units on a scale	Standard Deviation 7.59
AIN457 300 mg- SoR	Change From Baseline in Dermatology Life Quality Index (DLQI) Score. up to Week 52, (Maintenance)	Week 20	-11 Units on a scale	Standard Deviation 7.64
AIN457 300 mg- SoR	Change From Baseline in Dermatology Life Quality Index (DLQI) Score. up to Week 52, (Maintenance)	Week 24	-10.3 Units on a scale	Standard Deviation 7.71
AIN457 300 mg- SoR	Change From Baseline in Dermatology Life Quality Index (DLQI) Score. up to Week 52, (Maintenance)	Week 28	-9.5 Units on a scale	Standard Deviation 7.46
AIN457 300 mg- SoR	Change From Baseline in Dermatology Life Quality Index (DLQI) Score. up to Week 52, (Maintenance)	Week 16	-11.3 Units on a scale	Standard Deviation 7.58
AIN457 300 mg- SoR	Change From Baseline in Dermatology Life Quality Index (DLQI) Score. up to Week 52, (Maintenance)	Week 48	7.9 Units on a scale	Standard Deviation 7.02

Secondary

Change From Baseline in EQ-5D at Each Visit, up to Week 52, (Induction)

ED-5Q: Participant rated questionnaire to assess health related quality of life in terms of a single utility score. Five domains are assessed mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) each with three possible score: 1 indicates no problems, better state of health; 3 indicates worst state of health (example confined to bed) A visual analog scale (VAS) assesses the health status from 0 (worst possible health state) to 100 (best possible health state)

Time frame: Baseline to week 2, 4, 8, 12

Population: Full analysis set (FAS) - All patients to whom study treatment was assigned

Arm	Measure	Group	Value (MEAN)	Dispersion
AIN457150 mg- Induction Period Only(IPO)	Change From Baseline in EQ-5D at Each Visit, up to Week 52, (Induction)	Week 2	5.9 Units on a scale	Standard Deviation 14.64
AIN457150 mg- Induction Period Only(IPO)	Change From Baseline in EQ-5D at Each Visit, up to Week 52, (Induction)	Week 4	10.8 Units on a scale	Standard Deviation 17.79
AIN457150 mg- Induction Period Only(IPO)	Change From Baseline in EQ-5D at Each Visit, up to Week 52, (Induction)	Week 8	17.5 Units on a scale	Standard Deviation 20.79
AIN457150 mg- Induction Period Only(IPO)	Change From Baseline in EQ-5D at Each Visit, up to Week 52, (Induction)	Week 12	20.2 Units on a scale	Standard Deviation 23.47
AIN457 300 mg - IPO	Change From Baseline in EQ-5D at Each Visit, up to Week 52, (Induction)	Week 12	21.2 Units on a scale	Standard Deviation 24.08
AIN457 300 mg - IPO	Change From Baseline in EQ-5D at Each Visit, up to Week 52, (Induction)	Week 2	7.6 Units on a scale	Standard Deviation 12.86
AIN457 300 mg - IPO	Change From Baseline in EQ-5D at Each Visit, up to Week 52, (Induction)	Week 8	18.3 Units on a scale	Standard Deviation 21.51
AIN457 300 mg - IPO	Change From Baseline in EQ-5D at Each Visit, up to Week 52, (Induction)	Week 4	13.6 Units on a scale	Standard Deviation 18.63

Secondary

Change From Baseline in EQ-5D at Each Visit, up to Week 52, (Maintenance)

Time frame: Baseline to week 16, 20, 24, 28, 32, 36, 40, 44, 48, and Week 52.

Population: Full analysis set (FAS) - All patients to whom study treatment was assigned

Arm	Measure	Group	Value (MEAN)	Dispersion
AIN457 150 mg - Fixed Interval (FI)	Change From Baseline in EQ-5D at Each Visit, up to Week 52, (Maintenance)	Week 16	21.4 Units on a scale	Standard Deviation 25.11
AIN457 150 mg - Fixed Interval (FI)	Change From Baseline in EQ-5D at Each Visit, up to Week 52, (Maintenance)	Week 20	20.6 Units on a scale	Standard Deviation 25.07
AIN457 150 mg - Fixed Interval (FI)	Change From Baseline in EQ-5D at Each Visit, up to Week 52, (Maintenance)	Week 24	20.6 Units on a scale	Standard Deviation 25.05
AIN457 150 mg - Fixed Interval (FI)	Change From Baseline in EQ-5D at Each Visit, up to Week 52, (Maintenance)	Week 28	19.4 Units on a scale	Standard Deviation 26.46
AIN457 150 mg - Fixed Interval (FI)	Change From Baseline in EQ-5D at Each Visit, up to Week 52, (Maintenance)	Week 32	20.4 Units on a scale	Standard Deviation 24.95
AIN457 150 mg - Fixed Interval (FI)	Change From Baseline in EQ-5D at Each Visit, up to Week 52, (Maintenance)	Week 36	19.6 Units on a scale	Standard Deviation 25.79
AIN457 150 mg - Fixed Interval (FI)	Change From Baseline in EQ-5D at Each Visit, up to Week 52, (Maintenance)	Week 40	19.8 Units on a scale	Standard Deviation 25.39
AIN457 150 mg - Fixed Interval (FI)	Change From Baseline in EQ-5D at Each Visit, up to Week 52, (Maintenance)	Week 44	19.8 Units on a scale	Standard Deviation 25.53
AIN457 150 mg - Fixed Interval (FI)	Change From Baseline in EQ-5D at Each Visit, up to Week 52, (Maintenance)	Week 48	19.7 Units on a scale	Standard Deviation 25.33
AIN457 150 mg - Fixed Interval (FI)	Change From Baseline in EQ-5D at Each Visit, up to Week 52, (Maintenance)	Week 52	18.3 Units on a scale	Standard Deviation 25.63
AIN457 300 mg FI	Change From Baseline in EQ-5D at Each Visit, up to Week 52, (Maintenance)	Week 24	22.9 Units on a scale	Standard Deviation 23.32
AIN457 300 mg FI	Change From Baseline in EQ-5D at Each Visit, up to Week 52, (Maintenance)	Week 48	22.7 Units on a scale	Standard Deviation 22.85
AIN457 300 mg FI	Change From Baseline in EQ-5D at Each Visit, up to Week 52, (Maintenance)	Week 28	23 Units on a scale	Standard Deviation 22.71
AIN457 300 mg FI	Change From Baseline in EQ-5D at Each Visit, up to Week 52, (Maintenance)	Week 32	22.8 Units on a scale	Standard Deviation 23.22
AIN457 300 mg FI	Change From Baseline in EQ-5D at Each Visit, up to Week 52, (Maintenance)	Week 36	23 Units on a scale	Standard Deviation 22.67
AIN457 300 mg FI	Change From Baseline in EQ-5D at Each Visit, up to Week 52, (Maintenance)	Week 40	22.8 Units on a scale	Standard Deviation 22.69
AIN457 300 mg FI	Change From Baseline in EQ-5D at Each Visit, up to Week 52, (Maintenance)	Week 52	23 Units on a scale	Standard Deviation 22.4
AIN457 300 mg FI	Change From Baseline in EQ-5D at Each Visit, up to Week 52, (Maintenance)	Week 44	22.3 Units on a scale	Standard Deviation 23.1
AIN457 300 mg FI	Change From Baseline in EQ-5D at Each Visit, up to Week 52, (Maintenance)	Week 16	23 Units on a scale	Standard Deviation 22.44
AIN457 300 mg FI	Change From Baseline in EQ-5D at Each Visit, up to Week 52, (Maintenance)	Week 20	23 Units on a scale	Standard Deviation 23.27
AIN457 150 mg- Start of Relapse (SoR)	Change From Baseline in EQ-5D at Each Visit, up to Week 52, (Maintenance)	Week 44	15.4 Units on a scale	Standard Deviation 23.7
AIN457 150 mg- Start of Relapse (SoR)	Change From Baseline in EQ-5D at Each Visit, up to Week 52, (Maintenance)	Week 40	16.3 Units on a scale	Standard Deviation 23.53
AIN457 150 mg- Start of Relapse (SoR)	Change From Baseline in EQ-5D at Each Visit, up to Week 52, (Maintenance)	Week 52	16.7 Units on a scale	Standard Deviation 23.3
AIN457 150 mg- Start of Relapse (SoR)	Change From Baseline in EQ-5D at Each Visit, up to Week 52, (Maintenance)	Week 16	23.4 Units on a scale	Standard Deviation 25.31
AIN457 150 mg- Start of Relapse (SoR)	Change From Baseline in EQ-5D at Each Visit, up to Week 52, (Maintenance)	Week 28	19.3 Units on a scale	Standard Deviation 25.07
AIN457 150 mg- Start of Relapse (SoR)	Change From Baseline in EQ-5D at Each Visit, up to Week 52, (Maintenance)	Week 36	17.4 Units on a scale	Standard Deviation 24.3
AIN457 150 mg- Start of Relapse (SoR)	Change From Baseline in EQ-5D at Each Visit, up to Week 52, (Maintenance)	Week 48	16.2 Units on a scale	Standard Deviation 23.17
AIN457 150 mg- Start of Relapse (SoR)	Change From Baseline in EQ-5D at Each Visit, up to Week 52, (Maintenance)	Week 20	22.1 Units on a scale	Standard Deviation 26.04
AIN457 150 mg- Start of Relapse (SoR)	Change From Baseline in EQ-5D at Each Visit, up to Week 52, (Maintenance)	Week 32	17.9 Units on a scale	Standard Deviation 24.97
AIN457 150 mg- Start of Relapse (SoR)	Change From Baseline in EQ-5D at Each Visit, up to Week 52, (Maintenance)	Week 24	20 Units on a scale	Standard Deviation 26.66
AIN457 300 mg- SoR	Change From Baseline in EQ-5D at Each Visit, up to Week 52, (Maintenance)	Week 32	18.8 Units on a scale	Standard Deviation 25.9
AIN457 300 mg- SoR	Change From Baseline in EQ-5D at Each Visit, up to Week 52, (Maintenance)	Week 44	14.9 Units on a scale	Standard Deviation 26.81
AIN457 300 mg- SoR	Change From Baseline in EQ-5D at Each Visit, up to Week 52, (Maintenance)	Week 36	17.7 Units on a scale	Standard Deviation 26.15
AIN457 300 mg- SoR	Change From Baseline in EQ-5D at Each Visit, up to Week 52, (Maintenance)	Week 52	13.4 Units on a scale	Standard Deviation 25.68
AIN457 300 mg- SoR	Change From Baseline in EQ-5D at Each Visit, up to Week 52, (Maintenance)	Week 40	16.4 Units on a scale	Standard Deviation 26.38
AIN457 300 mg- SoR	Change From Baseline in EQ-5D at Each Visit, up to Week 52, (Maintenance)	Week 20	22.4 Units on a scale	Standard Deviation 27.45
AIN457 300 mg- SoR	Change From Baseline in EQ-5D at Each Visit, up to Week 52, (Maintenance)	Week 24	22.3 Units on a scale	Standard Deviation 26.47
AIN457 300 mg- SoR	Change From Baseline in EQ-5D at Each Visit, up to Week 52, (Maintenance)	Week 28	20.4 Units on a scale	Standard Deviation 26.26
AIN457 300 mg- SoR	Change From Baseline in EQ-5D at Each Visit, up to Week 52, (Maintenance)	Week 16	23.9 Units on a scale	Standard Deviation 26.09
AIN457 300 mg- SoR	Change From Baseline in EQ-5D at Each Visit, up to Week 52, (Maintenance)	Week 48	13.4 Units on a scale	Standard Deviation 26.65

Secondary

Median Time to Relapse (Weeks) From Week 12.

Median time to relapse (weeks) from week 12. Relapse is defined as greater than 50% loss of the maximal PASI improvement from baseline. PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4). A negative mean percentage change indicates improvement

Time frame: Week 12 to week 16, 20, 24, 28, 32, 36, 40, 44, 48, and Week 52.

Population: Full analysis set (FAS) - All patients to whom study treatment was assigned

Arm	Measure	Value (MEDIAN)
AIN457 150 mg - Fixed Interval (FI)	Median Time to Relapse (Weeks) From Week 12.	NA Number of weeks
AIN457 300 mg FI	Median Time to Relapse (Weeks) From Week 12.	NA Number of weeks
AIN457 150 mg- Start of Relapse (SoR)	Median Time to Relapse (Weeks) From Week 12.	NA Number of weeks
AIN457 300 mg- SoR	Median Time to Relapse (Weeks) From Week 12.	302 Number of weeks

Secondary

Number of Participants Developing Anti-secukinumab Antibodies

The development of anti-secunimubab anti-bodies will decrease a participant's ability to respond to secukinumab treatment. The number of participants developing anti-secukinumab anti-bodies was measured from Baseline to week 12, 24, 52 and 8 weeks after treatment at week 60

Time frame: Baseline, weeks 12, 24, 52 and 60

Population: Full analysis set (FAS) - All patients to whom study treatment was assigned

Arm	Measure	Value (NUMBER)
AIN457 150 mg - Fixed Interval (FI)	Number of Participants Developing Anti-secukinumab Antibodies	2 Number of participants
AIN457 300 mg FI	Number of Participants Developing Anti-secukinumab Antibodies	1 Number of participants
AIN457 150 mg- Start of Relapse (SoR)	Number of Participants Developing Anti-secukinumab Antibodies	1 Number of participants
AIN457 300 mg- SoR	Number of Participants Developing Anti-secukinumab Antibodies	1 Number of participants

Secondary

Number of Secukinumab Injections Needed to Regain PASI 75 Response From Start of Relapse After Week 12

The number of secukinumab injections needed for participants to regain PASI 75 response from the start of relapse after week 12

Time frame: week 16, 20, 24,28,32,36,40,44,48,and Week 52

Population: Full analysis set (FAS) - All patients to whom study treatment was assigned

Arm	Measure	Group	Value (NUMBER)
AIN457 150 mg- Start of Relapse (SoR)	Number of Secukinumab Injections Needed to Regain PASI 75 Response From Start of Relapse After Week 12	SoR: one, Regain PASI 75 Injection 10 (n=97,128)	0 percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Number of Secukinumab Injections Needed to Regain PASI 75 Response From Start of Relapse After Week 12	SoR: one, Regain PASI 75 Injection 12 (n=97,128)	0 percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Number of Secukinumab Injections Needed to Regain PASI 75 Response From Start of Relapse After Week 12	SoR: one, Regain PASI 75 Injection 4 (n=97,128)	6.2 percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Number of Secukinumab Injections Needed to Regain PASI 75 Response From Start of Relapse After Week 12	SoR: Two, Regain PASI 75 Injection 0 (n=21,36)	0 percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Number of Secukinumab Injections Needed to Regain PASI 75 Response From Start of Relapse After Week 12	SoR: one, Regain PASI 75 Injection 1 (n=97,128)	40.2 percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Number of Secukinumab Injections Needed to Regain PASI 75 Response From Start of Relapse After Week 12	SoR: Two, Regain PASI 75 Injection 1 (n=21,36)	47.6 percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Number of Secukinumab Injections Needed to Regain PASI 75 Response From Start of Relapse After Week 12	SoR: one, Regain PASI 75 Injection 5 (n=97,128)	4.1 percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Number of Secukinumab Injections Needed to Regain PASI 75 Response From Start of Relapse After Week 12	SoR: Two, Regain PASI 75 Injection 2 (n=21,36)	42.9 percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Number of Secukinumab Injections Needed to Regain PASI 75 Response From Start of Relapse After Week 12	SoR: one, Regain PASI 75 Injection 0 (n=97,128)	4.1 percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Number of Secukinumab Injections Needed to Regain PASI 75 Response From Start of Relapse After Week 12	SoR: Two, Regain PASI 75 Injection 3 (n=21,36)	4.8 percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Number of Secukinumab Injections Needed to Regain PASI 75 Response From Start of Relapse After Week 12	SoR: one, Regain PASI 75 Injection 6 (n=97,128)	4.1 percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Number of Secukinumab Injections Needed to Regain PASI 75 Response From Start of Relapse After Week 12	SoR: Two, Regain PASI 75 Injection 4 (n=21,36)	0 percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Number of Secukinumab Injections Needed to Regain PASI 75 Response From Start of Relapse After Week 12	SoR: one, Regain PASI 75 Injection 2 (n=97,128)	27.8 percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Number of Secukinumab Injections Needed to Regain PASI 75 Response From Start of Relapse After Week 12	SoR: Two, Regain PASI 75 Injection 6 (n=21,36)	4.8 percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Number of Secukinumab Injections Needed to Regain PASI 75 Response From Start of Relapse After Week 12	SoR: one, Regain PASI 75 Injection 7 (n=97,128)	1 percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Number of Secukinumab Injections Needed to Regain PASI 75 Response From Start of Relapse After Week 12	SoR: Two, Regain PASI 75 Injection 8 (n=21,36)	0 percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Number of Secukinumab Injections Needed to Regain PASI 75 Response From Start of Relapse After Week 12	SoR: one, Regain PASI 75 Injection 3 (n=97,128)	11.3 percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Number of Secukinumab Injections Needed to Regain PASI 75 Response From Start of Relapse After Week 12	SoR: Three, Regain PASI 75 Injection 2 (n=0,4)	NA percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Number of Secukinumab Injections Needed to Regain PASI 75 Response From Start of Relapse After Week 12	SoR: one, Regain PASI 75 Injection 8 (n=97,128)	1 percent of participants
AIN457 300 mg- SoR	Number of Secukinumab Injections Needed to Regain PASI 75 Response From Start of Relapse After Week 12	SoR: Three, Regain PASI 75 Injection 2 (n=0,4)	100 percent of participants
AIN457 300 mg- SoR	Number of Secukinumab Injections Needed to Regain PASI 75 Response From Start of Relapse After Week 12	SoR: one, Regain PASI 75 Injection 10 (n=97,128)	3.9 percent of participants
AIN457 300 mg- SoR	Number of Secukinumab Injections Needed to Regain PASI 75 Response From Start of Relapse After Week 12	SoR: one, Regain PASI 75 Injection 0 (n=97,128)	0.8 percent of participants
AIN457 300 mg- SoR	Number of Secukinumab Injections Needed to Regain PASI 75 Response From Start of Relapse After Week 12	SoR: one, Regain PASI 75 Injection 1 (n=97,128)	0 percent of participants
AIN457 300 mg- SoR	Number of Secukinumab Injections Needed to Regain PASI 75 Response From Start of Relapse After Week 12	SoR: one, Regain PASI 75 Injection 3 (n=97,128)	0 percent of participants
AIN457 300 mg- SoR	Number of Secukinumab Injections Needed to Regain PASI 75 Response From Start of Relapse After Week 12	SoR: one, Regain PASI 75 Injection 4 (n=97,128)	31.3 percent of participants
AIN457 300 mg- SoR	Number of Secukinumab Injections Needed to Regain PASI 75 Response From Start of Relapse After Week 12	SoR: one, Regain PASI 75 Injection 5 (n=97,128)	0 percent of participants
AIN457 300 mg- SoR	Number of Secukinumab Injections Needed to Regain PASI 75 Response From Start of Relapse After Week 12	SoR: one, Regain PASI 75 Injection 6 (n=97,128)	14.1 percent of participants
AIN457 300 mg- SoR	Number of Secukinumab Injections Needed to Regain PASI 75 Response From Start of Relapse After Week 12	SoR: one, Regain PASI 75 Injection 7 (n=97,128)	0 percent of participants
AIN457 300 mg- SoR	Number of Secukinumab Injections Needed to Regain PASI 75 Response From Start of Relapse After Week 12	SoR: one, Regain PASI 75 Injection 8 (n=97,128)	3.1 percent of participants
AIN457 300 mg- SoR	Number of Secukinumab Injections Needed to Regain PASI 75 Response From Start of Relapse After Week 12	SoR: one, Regain PASI 75 Injection 12 (n=97,128)	1.6 percent of participants
AIN457 300 mg- SoR	Number of Secukinumab Injections Needed to Regain PASI 75 Response From Start of Relapse After Week 12	SoR: Two, Regain PASI 75 Injection 0 (n=21,36)	5.6 percent of participants
AIN457 300 mg- SoR	Number of Secukinumab Injections Needed to Regain PASI 75 Response From Start of Relapse After Week 12	SoR: Two, Regain PASI 75 Injection 1 (n=21,36)	0 percent of participants
AIN457 300 mg- SoR	Number of Secukinumab Injections Needed to Regain PASI 75 Response From Start of Relapse After Week 12	SoR: Two, Regain PASI 75 Injection 2 (n=21,36)	58.3 percent of participants
AIN457 300 mg- SoR	Number of Secukinumab Injections Needed to Regain PASI 75 Response From Start of Relapse After Week 12	SoR: Two, Regain PASI 75 Injection 3 (n=21,36)	0 percent of participants
AIN457 300 mg- SoR	Number of Secukinumab Injections Needed to Regain PASI 75 Response From Start of Relapse After Week 12	SoR: Two, Regain PASI 75 Injection 4 (n=21,36)	19.4 percent of participants
AIN457 300 mg- SoR	Number of Secukinumab Injections Needed to Regain PASI 75 Response From Start of Relapse After Week 12	SoR: Two, Regain PASI 75 Injection 6 (n=21,36)	8.3 percent of participants
AIN457 300 mg- SoR	Number of Secukinumab Injections Needed to Regain PASI 75 Response From Start of Relapse After Week 12	SoR: Two, Regain PASI 75 Injection 8 (n=21,36)	8.3 percent of participants
AIN457 300 mg- SoR	Number of Secukinumab Injections Needed to Regain PASI 75 Response From Start of Relapse After Week 12	SoR: one, Regain PASI 75 Injection 2 (n=97,128)	45.3 percent of participants

Secondary

Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1

PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4). PASI 50, 75, 90 and 100 were defined as participants achieving ≥ 50%, 75%, 90% or 100% improvement from baseline. The IGA mod 2011 scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate and 4 = severe.

Time frame: Week 16, 20, 24,28,32,36,40,44,48,and Week 52

Population: Full analysis set (FAS) - All patients to whom study treatment was assigned

Arm	Measure	Group	Value (NUMBER)
AIN457 150 mg - Fixed Interval (FI)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 100 Visit 8	2.5 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 50 Visit 8	3 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 100 Visit 7	4.4 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 50 Visit 0	1.5 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 50 Visit 1	1 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 50 Visit 2	2.5 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 50 Visit 3	0.5 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 50 Visit 4	1.5 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 50 Visit 5	3.4 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 50 Visit 6	2.5 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 50 Visit 7	3 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 50 Visit 9	8.4 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 50 Visit 10	72.9 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 75 Visit 0	4.9 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 75 Visit 1	5.9 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 75 Visit 2	5.4 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 75 Visit 3	3 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 75 Visit 4	4.9 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 75 Visit 5	3.4 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 75 Visit 6	4.9 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 75 Visit 7	4.4 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 75 Visit 8	2.5 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 75 Visit 9	7.4 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 75 Visit 10	53.2 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 90 Visit 0	24.6 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 90 Visit 1	4.4 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 90 Visit 2	2.5 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 90 Visit 3	5.4 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 90 Visit 4	4.4 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 90 Visit 5	3.9 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 90 Visit 6	3.4 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 90 Visit 7	3.9 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 90 Visit 8	5.4 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 90 Visit 9	13.8 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 90 Visit 10	28.1 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 100 Visit 0	53.2 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 100 Visit 1	5.9 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 100 Visit 2	5.9 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 100 Visit 3	3.4 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 100 Visit 4	3.4 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 100 Visit 5	3 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 100 Visit 9	4.4 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 100 Visit 10	8.9 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	IGA mod 2011 0 or 1 response Visit 0	19.2 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	IGA mod 2011 0 or 1 response Visit 1	5.4 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	IGA mod 2011 0 or 1 response Visit 2	2 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	IGA mod 2011 0 or 1 response Visit 3	5.4 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	IGA mod 2011 0 or 1 response Visit 4	3.9 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	IGA mod 2011 0 or 1 response Visit 5	3.4 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	IGA mod 2011 0 or 1 response Visit 6	6.4 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	IGA mod 2011 0 or 1 response Visit 7	6.4 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	IGA mod 2011 0 or 1 response Visit 8	5.9 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	IGA mod 2011 0 or 1 response Visit 9	6.4 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	IGA mod 2011 0 or 1 response Visit 10	35.5 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 100 Visit 6	4.9 Percent of participants
AIN457 300 mg FI	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 50 Visit 4	2.8 Percent of participants
AIN457 300 mg FI	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 90 Visit 2	3.7 Percent of participants
AIN457 300 mg FI	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 75 Visit 3	3.2 Percent of participants
AIN457 300 mg FI	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 75 Visit 4	1.9 Percent of participants
AIN457 300 mg FI	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 100 Visit 8	5.6 Percent of participants
AIN457 300 mg FI	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 90 Visit 3	4.2 Percent of participants
AIN457 300 mg FI	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 75 Visit 0	3.2 Percent of participants
AIN457 300 mg FI	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	IGA mod 2011 0 or 1 response Visit 1	3.7 Percent of participants
AIN457 300 mg FI	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 90 Visit 4	2.3 Percent of participants
AIN457 300 mg FI	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 50 Visit 3	1.9 Percent of participants
AIN457 300 mg FI	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 100 Visit 4	2.3 Percent of participants
AIN457 300 mg FI	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 50 Visit 10	79.6 Percent of participants
AIN457 300 mg FI	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 90 Visit 5	1.4 Percent of participants
AIN457 300 mg FI	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 75 Visit 5	1.9 Percent of participants
AIN457 300 mg FI	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	IGA mod 2011 0 or 1 response Visit 10	47.2 Percent of participants
AIN457 300 mg FI	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 100 Visit 3	4.6 Percent of participants
AIN457 300 mg FI	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 90 Visit 6	5.1 Percent of participants
AIN457 300 mg FI	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 50 Visit 6	0.5 Percent of participants
AIN457 300 mg FI	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 100 Visit 2	4.2 Percent of participants
AIN457 300 mg FI	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 100 Visit 1	6.5 Percent of participants
AIN457 300 mg FI	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 90 Visit 7	4.6 Percent of participants
AIN457 300 mg FI	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 50 Visit 2	0.5 Percent of participants
AIN457 300 mg FI	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	IGA mod 2011 0 or 1 response Visit 6	4.6 Percent of participants
AIN457 300 mg FI	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	IGA mod 2011 0 or 1 response Visit 5	1.9 Percent of participants
AIN457 300 mg FI	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 90 Visit 8	6.5 Percent of participants
AIN457 300 mg FI	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 100 Visit 9	7.9 Percent of participants
AIN457 300 mg FI	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 100 Visit 0	41.2 Percent of participants
AIN457 300 mg FI	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 75 Visit 6	1.9 Percent of participants
AIN457 300 mg FI	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 90 Visit 9	13.4 Percent of participants
AIN457 300 mg FI	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 90 Visit 10	41.7 Percent of participants
AIN457 300 mg FI	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 50 Visit 8	1.9 Percent of participants
AIN457 300 mg FI	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 50 Visit 1	0.5 Percent of participants
AIN457 300 mg FI	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 50 Visit 0	0.9 Percent of participants
AIN457 300 mg FI	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 75 Visit 7	3.7 Percent of participants
AIN457 300 mg FI	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 75 Visit 1	2.8 Percent of participants
AIN457 300 mg FI	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 100 Visit 7	3.7 Percent of participants
AIN457 300 mg FI	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	IGA mod 2011 0 or 1 response Visit 2	3.7 Percent of participants
AIN457 300 mg FI	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 75 Visit 8	4.2 Percent of participants
AIN457 300 mg FI	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 50 Visit 7	3.2 Percent of participants
AIN457 300 mg FI	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 100 Visit 6	5.1 Percent of participants
AIN457 300 mg FI	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 100 Visit 10	13.4 Percent of participants
AIN457 300 mg FI	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 75 Visit 9	8.8 Percent of participants
AIN457 300 mg FI	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 50 Visit 5	0.5 Percent of participants
AIN457 300 mg FI	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 50 Visit 9	7.9 Percent of participants
AIN457 300 mg FI	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	IGA mod 2011 0 or 1 response Visit 7	3.7 Percent of participants
AIN457 300 mg FI	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 75 Visit 10	65.7 Percent of participants
AIN457 300 mg FI	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 75 Visit 2	2.8 Percent of participants
AIN457 300 mg FI	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	IGA mod 2011 0 or 1 response Visit 4	3.2 Percent of participants
AIN457 300 mg FI	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	IGA mod 2011 0 or 1 response Visit 9	12.5 Percent of participants
AIN457 300 mg FI	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 90 Visit 0	12 Percent of participants
AIN457 300 mg FI	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	IGA mod 2011 0 or 1 response Visit 0	11.6 Percent of participants
AIN457 300 mg FI	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 100 Visit 5	5.6 Percent of participants
AIN457 300 mg FI	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	IGA mod 2011 0 or 1 response Visit 3	5.1 Percent of participants
AIN457 300 mg FI	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	IGA mod 2011 0 or 1 response Visit 8	2.8 Percent of participants
AIN457 300 mg FI	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 90 Visit 1	5.1 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	IGA mod 2011 0 or 1 response Visit 7	7.8 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 50 Visit 9	8.7 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	IGA mod 2011 0 or 1 response Visit 8	5.8 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 50 Visit 10	53.9 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 75 Visit 0	3.9 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	IGA mod 2011 0 or 1 response Visit 0	20.4 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 75 Visit 1	6.8 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 75 Visit 2	8.3 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 75 Visit 3	7.8 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	IGA mod 2011 0 or 1 response Visit 1	10.2 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 75 Visit 5	10.7 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 75 Visit 6	11.7 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 75 Visit 7	9.2 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 75 Visit 8	9.7 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	IGA mod 2011 0 or 1 response Visit 2	9.7 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 75 Visit 9	10.7 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 75 Visit 10	10.2 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 90 Visit 0	23.8 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 90 Visit 1	15 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	IGA mod 2011 0 or 1 response Visit 3	9.2 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 90 Visit 2	8.3 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 90 Visit 3	6.8 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	IGA mod 2011 0 or 1 response Visit 9	3.9 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 90 Visit 4	11.2 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	IGA mod 2011 0 or 1 response Visit 4	8.3 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 90 Visit 5	8.7 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 90 Visit 6	9.7 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 90 Visit 7	7.3 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 90 Visit 8	2.9 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	IGA mod 2011 0 or 1 response Visit 5	10.2 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 90 Visit 10	3.4 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 100 Visit 0	65 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 100 Visit 1	9.7 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	IGA mod 2011 0 or 1 response Visit 6	9.2 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 100 Visit 2	6.3 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 100 Visit 3	7.3 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 100 Visit 4	6.3 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 100 Visit 5	2.9 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 50 Visit 1	1.5 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 50 Visit 7	6.8 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 75 Visit 4	11.2 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 90 Visit 9	2.9 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 100 Visit 6	1 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 100 Visit 8	0 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 100 Visit 7	0.5 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 50 Visit 0	0.5 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	IGA mod 2011 0 or 1 response Visit 10	5.3 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 50 Visit 2	3.4 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 100 Visit 9	0 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 50 Visit 3	3.4 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 50 Visit 4	4.4 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 50 Visit 5	2.4 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 50 Visit 6	4.9 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 100 Visit 10	1 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 50 Visit 8	10.2 Percent of participants
AIN457 300 mg- SoR	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 50 Visit 7	5.5 Percent of participants
AIN457 300 mg- SoR	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 50 Visit 4	1.8 Percent of participants
AIN457 300 mg- SoR	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	IGA mod 2011 0 or 1 response Visit 3	10.6 Percent of participants
AIN457 300 mg- SoR	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 75 Visit 3	6.9 Percent of participants
AIN457 300 mg- SoR	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 90 Visit 2	12 Percent of participants
AIN457 300 mg- SoR	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 75 Visit 2	4.1 Percent of participants
AIN457 300 mg- SoR	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 90 Visit 1	7.8 Percent of participants
AIN457 300 mg- SoR	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 90 Visit 3	11.1 Percent of participants
AIN457 300 mg- SoR	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	IGA mod 2011 0 or 1 response Visit 0	12 Percent of participants
AIN457 300 mg- SoR	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 100 Visit 0	51.2 Percent of participants
AIN457 300 mg- SoR	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 90 Visit 0	15.7 Percent of participants
AIN457 300 mg- SoR	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 100 Visit 7	2.3 Percent of participants
AIN457 300 mg- SoR	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 75 Visit 10	12 Percent of participants
AIN457 300 mg- SoR	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	IGA mod 2011 0 or 1 response Visit 2	7.4 Percent of participants
AIN457 300 mg- SoR	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 75 Visit 9	15.2 Percent of participants
AIN457 300 mg- SoR	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 75 Visit 8	18.4 Percent of participants
AIN457 300 mg- SoR	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 50 Visit 9	16.6 Percent of participants
AIN457 300 mg- SoR	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 100 Visit 6	1.8 Percent of participants
AIN457 300 mg- SoR	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 50 Visit 5	1.8 Percent of participants
AIN457 300 mg- SoR	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 100 Visit 8	0.9 Percent of participants
AIN457 300 mg- SoR	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 75 Visit 7	11.1 Percent of participants
AIN457 300 mg- SoR	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 75 Visit 1	2.3 Percent of participants
AIN457 300 mg- SoR	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	IGA mod 2011 0 or 1 response Visit 10	5.5 Percent of participants
AIN457 300 mg- SoR	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 75 Visit 0	2.8 Percent of participants
AIN457 300 mg- SoR	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 50 Visit 0	0.5 Percent of participants
AIN457 300 mg- SoR	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 100 Visit 10	0.9 Percent of participants
AIN457 300 mg- SoR	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 75 Visit 6	8.3 Percent of participants
AIN457 300 mg- SoR	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 50 Visit 1	0.5 Percent of participants
AIN457 300 mg- SoR	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	IGA mod 2011 0 or 1 response Visit 1	6.5 Percent of participants
AIN457 300 mg- SoR	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 75 Visit 5	10.6 Percent of participants
AIN457 300 mg- SoR	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	IGA mod 2011 0 or 1 response Visit 5	13.8 Percent of participants
AIN457 300 mg- SoR	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 90 Visit 9	3.7 Percent of participants
AIN457 300 mg- SoR	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 50 Visit 6	0.9 Percent of participants
AIN457 300 mg- SoR	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 90 Visit 10	4.6 Percent of participants
AIN457 300 mg- SoR	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 100 Visit 5	6.5 Percent of participants
AIN457 300 mg- SoR	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 90 Visit 8	8.3 Percent of participants
AIN457 300 mg- SoR	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 50 Visit 2	0.5 Percent of participants
AIN457 300 mg- SoR	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 90 Visit 7	10.6 Percent of participants
AIN457 300 mg- SoR	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	IGA mod 2011 0 or 1 response Visit 9	6 Percent of participants
AIN457 300 mg- SoR	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 50 Visit 8	12.4 Percent of participants
AIN457 300 mg- SoR	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 100 Visit 1	7.8 Percent of participants
AIN457 300 mg- SoR	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 75 Visit 4	8.3 Percent of participants
AIN457 300 mg- SoR	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 90 Visit 6	8.8 Percent of participants
AIN457 300 mg- SoR	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 50 Visit 10	59 Percent of participants
AIN457 300 mg- SoR	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 100 Visit 2	12.4 Percent of participants
AIN457 300 mg- SoR	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	IGA mod 2011 0 or 1 response Visit 6	7.8 Percent of participants
AIN457 300 mg- SoR	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	IGA mod 2011 0 or 1 response Visit 4	12 Percent of participants
AIN457 300 mg- SoR	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 50 Visit 3	0.5 Percent of participants
AIN457 300 mg- SoR	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 100 Visit 3	8.8 Percent of participants
AIN457 300 mg- SoR	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 90 Visit 5	6.5 Percent of participants
AIN457 300 mg- SoR	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 90 Visit 4	11.1 Percent of participants
AIN457 300 mg- SoR	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 100 Visit 9	0.5 Percent of participants
AIN457 300 mg- SoR	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	PASI 100 Visit 4	6.9 Percent of participants
AIN457 300 mg- SoR	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	IGA mod 2011 0 or 1 response Visit 7	10.1 Percent of participants
AIN457 300 mg- SoR	Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1	IGA mod 2011 0 or 1 response Visit 8	8.3 Percent of participants

Secondary

% of Participants Achieving a DLQI Score of 0 or 1 at Each Visit up to Week 52, (Induction)

Time frame: Baseline to week 2, 4, 6, 8, 12

Population: Full analysis set (FAS) - All patients to whom study treatment was assigned

Arm	Measure	Group	Value (NUMBER)
AIN457150 mg- Induction Period Only(IPO)	% of Participants Achieving a DLQI Score of 0 or 1 at Each Visit up to Week 52, (Induction)	Week 2 (n=463,471)	9.5 Percent of participants
AIN457150 mg- Induction Period Only(IPO)	% of Participants Achieving a DLQI Score of 0 or 1 at Each Visit up to Week 52, (Induction)	Week 4 (n=479,482)	23.2 Percent of participants
AIN457150 mg- Induction Period Only(IPO)	% of Participants Achieving a DLQI Score of 0 or 1 at Each Visit up to Week 52, (Induction)	Week 8 (n=479,482)	44.7 Percent of participants
AIN457150 mg- Induction Period Only(IPO)	% of Participants Achieving a DLQI Score of 0 or 1 at Each Visit up to Week 52, (Induction)	Week 12 (n=479,482)	53.4 Percent of participants
AIN457 300 mg - IPO	% of Participants Achieving a DLQI Score of 0 or 1 at Each Visit up to Week 52, (Induction)	Week 12 (n=479,482)	63.1 Percent of participants
AIN457 300 mg - IPO	% of Participants Achieving a DLQI Score of 0 or 1 at Each Visit up to Week 52, (Induction)	Week 2 (n=463,471)	13.8 Percent of participants
AIN457 300 mg - IPO	% of Participants Achieving a DLQI Score of 0 or 1 at Each Visit up to Week 52, (Induction)	Week 8 (n=479,482)	52.1 Percent of participants
AIN457 300 mg - IPO	% of Participants Achieving a DLQI Score of 0 or 1 at Each Visit up to Week 52, (Induction)	Week 4 (n=479,482)	33.2 Percent of participants

Secondary

% of Participants Achieving a DLQI Score of 0 or 1 at Each Visit up to Week 52, (Maintenance).

Time frame: Baseline to week 16, 20, 24, 28, 32, 36, 40, 44, 48, and Week 52

Population: Full analysis set (FAS) - All patients to whom study treatment was assigned

Arm	Measure	Group	Value (NUMBER)
AIN457 150 mg - Fixed Interval (FI)	% of Participants Achieving a DLQI Score of 0 or 1 at Each Visit up to Week 52, (Maintenance).	Week 20 (n=202,213,205,217)	57.4 Percent of participant
AIN457 150 mg - Fixed Interval (FI)	% of Participants Achieving a DLQI Score of 0 or 1 at Each Visit up to Week 52, (Maintenance).	Week 24 (n=202,214,206,217)	58.4 Percent of participant
AIN457 150 mg - Fixed Interval (FI)	% of Participants Achieving a DLQI Score of 0 or 1 at Each Visit up to Week 52, (Maintenance).	Week 16 (n=199,209,202,215)	59.8 Percent of participant
AIN457 150 mg - Fixed Interval (FI)	% of Participants Achieving a DLQI Score of 0 or 1 at Each Visit up to Week 52, (Maintenance).	Week 28 (n=202,214,206,217)	57.9 Percent of participant
AIN457 150 mg - Fixed Interval (FI)	% of Participants Achieving a DLQI Score of 0 or 1 at Each Visit up to Week 52, (Maintenance).	Week 32 (n=202,214,206,217)	57.9 Percent of participant
AIN457 150 mg - Fixed Interval (FI)	% of Participants Achieving a DLQI Score of 0 or 1 at Each Visit up to Week 52, (Maintenance).	Week 36 (n=202,214,206,217)	58.4 Percent of participant
AIN457 150 mg - Fixed Interval (FI)	% of Participants Achieving a DLQI Score of 0 or 1 at Each Visit up to Week 52, (Maintenance).	Week 40 (n=202,214,206,217)	55 Percent of participant
AIN457 150 mg - Fixed Interval (FI)	% of Participants Achieving a DLQI Score of 0 or 1 at Each Visit up to Week 52, (Maintenance).	Week 44 (n=202,214,206,217)	59.9 Percent of participant
AIN457 150 mg - Fixed Interval (FI)	% of Participants Achieving a DLQI Score of 0 or 1 at Each Visit up to Week 52, (Maintenance).	Week 48 (n=202,214,206,217)	54 Percent of participant
AIN457 150 mg - Fixed Interval (FI)	% of Participants Achieving a DLQI Score of 0 or 1 at Each Visit up to Week 52, (Maintenance).	Week 52 (n=202,214,206,217)	56.4 Percent of participant
AIN457 300 mg FI	% of Participants Achieving a DLQI Score of 0 or 1 at Each Visit up to Week 52, (Maintenance).	Week 44 (n=202,214,206,217)	68.7 Percent of participant
AIN457 300 mg FI	% of Participants Achieving a DLQI Score of 0 or 1 at Each Visit up to Week 52, (Maintenance).	Week 36 (n=202,214,206,217)	65 Percent of participant
AIN457 300 mg FI	% of Participants Achieving a DLQI Score of 0 or 1 at Each Visit up to Week 52, (Maintenance).	Week 48 (n=202,214,206,217)	67.3 Percent of participant
AIN457 300 mg FI	% of Participants Achieving a DLQI Score of 0 or 1 at Each Visit up to Week 52, (Maintenance).	Week 52 (n=202,214,206,217)	69.2 Percent of participant
AIN457 300 mg FI	% of Participants Achieving a DLQI Score of 0 or 1 at Each Visit up to Week 52, (Maintenance).	Week 40 (n=202,214,206,217)	66.4 Percent of participant
AIN457 300 mg FI	% of Participants Achieving a DLQI Score of 0 or 1 at Each Visit up to Week 52, (Maintenance).	Week 28 (n=202,214,206,217)	70.1 Percent of participant
AIN457 300 mg FI	% of Participants Achieving a DLQI Score of 0 or 1 at Each Visit up to Week 52, (Maintenance).	Week 24 (n=202,214,206,217)	68.7 Percent of participant
AIN457 300 mg FI	% of Participants Achieving a DLQI Score of 0 or 1 at Each Visit up to Week 52, (Maintenance).	Week 32 (n=202,214,206,217)	67.8 Percent of participant
AIN457 300 mg FI	% of Participants Achieving a DLQI Score of 0 or 1 at Each Visit up to Week 52, (Maintenance).	Week 16 (n=199,209,202,215)	66.5 Percent of participant
AIN457 300 mg FI	% of Participants Achieving a DLQI Score of 0 or 1 at Each Visit up to Week 52, (Maintenance).	Week 20 (n=202,213,205,217)	67.6 Percent of participant
AIN457 150 mg- Start of Relapse (SoR)	% of Participants Achieving a DLQI Score of 0 or 1 at Each Visit up to Week 52, (Maintenance).	Week 16 (n=199,209,202,215)	58.4 Percent of participant
AIN457 150 mg- Start of Relapse (SoR)	% of Participants Achieving a DLQI Score of 0 or 1 at Each Visit up to Week 52, (Maintenance).	Week 24 (n=202,214,206,217)	53.9 Percent of participant
AIN457 150 mg- Start of Relapse (SoR)	% of Participants Achieving a DLQI Score of 0 or 1 at Each Visit up to Week 52, (Maintenance).	Week 48 (n=202,214,206,217)	32 Percent of participant
AIN457 150 mg- Start of Relapse (SoR)	% of Participants Achieving a DLQI Score of 0 or 1 at Each Visit up to Week 52, (Maintenance).	Week 32 (n=202,214,206,217)	37.9 Percent of participant
AIN457 150 mg- Start of Relapse (SoR)	% of Participants Achieving a DLQI Score of 0 or 1 at Each Visit up to Week 52, (Maintenance).	Week 36 (n=202,214,206,217)	39.8 Percent of participant
AIN457 150 mg- Start of Relapse (SoR)	% of Participants Achieving a DLQI Score of 0 or 1 at Each Visit up to Week 52, (Maintenance).	Week 40 (n=202,214,206,217)	35 Percent of participant
AIN457 150 mg- Start of Relapse (SoR)	% of Participants Achieving a DLQI Score of 0 or 1 at Each Visit up to Week 52, (Maintenance).	Week 44 (n=202,214,206,217)	31.6 Percent of participant
AIN457 150 mg- Start of Relapse (SoR)	% of Participants Achieving a DLQI Score of 0 or 1 at Each Visit up to Week 52, (Maintenance).	Week 20 (n=202,213,205,217)	58 Percent of participant
AIN457 150 mg- Start of Relapse (SoR)	% of Participants Achieving a DLQI Score of 0 or 1 at Each Visit up to Week 52, (Maintenance).	Week 28 (n=202,214,206,217)	47.6 Percent of participant
AIN457 150 mg- Start of Relapse (SoR)	% of Participants Achieving a DLQI Score of 0 or 1 at Each Visit up to Week 52, (Maintenance).	Week 52 (n=202,214,206,217)	31.1 Percent of participant
AIN457 300 mg- SoR	% of Participants Achieving a DLQI Score of 0 or 1 at Each Visit up to Week 52, (Maintenance).	Week 24 (n=202,214,206,217)	65.4 Percent of participant
AIN457 300 mg- SoR	% of Participants Achieving a DLQI Score of 0 or 1 at Each Visit up to Week 52, (Maintenance).	Week 32 (n=202,214,206,217)	47.5 Percent of participant
AIN457 300 mg- SoR	% of Participants Achieving a DLQI Score of 0 or 1 at Each Visit up to Week 52, (Maintenance).	Week 16 (n=199,209,202,215)	72.1 Percent of participant
AIN457 300 mg- SoR	% of Participants Achieving a DLQI Score of 0 or 1 at Each Visit up to Week 52, (Maintenance).	Week 20 (n=202,213,205,217)	69.6 Percent of participant
AIN457 300 mg- SoR	% of Participants Achieving a DLQI Score of 0 or 1 at Each Visit up to Week 52, (Maintenance).	Week 44 (n=202,214,206,217)	43.3 Percent of participant
AIN457 300 mg- SoR	% of Participants Achieving a DLQI Score of 0 or 1 at Each Visit up to Week 52, (Maintenance).	Week 52 (n=202,214,206,217)	37.3 Percent of participant
AIN457 300 mg- SoR	% of Participants Achieving a DLQI Score of 0 or 1 at Each Visit up to Week 52, (Maintenance).	Week 28 (n=202,214,206,217)	51.6 Percent of participant
AIN457 300 mg- SoR	% of Participants Achieving a DLQI Score of 0 or 1 at Each Visit up to Week 52, (Maintenance).	Week 40 (n=202,214,206,217)	42.4 Percent of participant
AIN457 300 mg- SoR	% of Participants Achieving a DLQI Score of 0 or 1 at Each Visit up to Week 52, (Maintenance).	Week 36 (n=202,214,206,217)	39.6 Percent of participant
AIN457 300 mg- SoR	% of Participants Achieving a DLQI Score of 0 or 1 at Each Visit up to Week 52, (Maintenance).	Week 48 (n=202,214,206,217)	40.6 Percent of participant

Secondary

Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Induction)

Time frame: Baseline, week 2, 4, 6, 8, 12

Population: Full analysis set (FAS) - All patients to whom study treatment was assigned

Arm	Measure	Group	Value (NUMBER)
AIN457150 mg- Induction Period Only(IPO)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Induction)	Week 4 PASI 50	66.3 Percent of participant
AIN457150 mg- Induction Period Only(IPO)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Induction)	Week 3 PASI 50	43 Percent of participant
AIN457150 mg- Induction Period Only(IPO)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Induction)	Week 3 PASI 90	1.5 Percent of participant
AIN457150 mg- Induction Period Only(IPO)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Induction)	Week 3 PASI 100	0 Percent of participant
AIN457150 mg- Induction Period Only(IPO)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Induction)	Week 2 PASI 75	1.9 Percent of participant
AIN457150 mg- Induction Period Only(IPO)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Induction)	Week 4 PASI 90	6.7 Percent of participant
AIN457150 mg- Induction Period Only(IPO)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Induction)	Week 3 IGA 0/1	5.2 Percent of participant
AIN457150 mg- Induction Period Only(IPO)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Induction)	Week 4 PASI 100	0.4 Percent of participant
AIN457150 mg- Induction Period Only(IPO)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Induction)	Week 8 IGA 0/1	47.8 Percent of participant
AIN457150 mg- Induction Period Only(IPO)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Induction)	Week 8 PASI 50	88.4 Percent of participant
AIN457150 mg- Induction Period Only(IPO)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Induction)	Week 8 PASI 75	63.8 Percent of participant
AIN457150 mg- Induction Period Only(IPO)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Induction)	Week 3 PASI 75	11 Percent of participant
AIN457150 mg- Induction Period Only(IPO)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Induction)	Week 12 IGA 0/1	62.8 Percent of participant
AIN457150 mg- Induction Period Only(IPO)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Induction)	Week 8 PASI 90	32.4 Percent of participant
AIN457150 mg- Induction Period Only(IPO)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Induction)	Week 2 PASI 50	20.2 Percent of participant
AIN457150 mg- Induction Period Only(IPO)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Induction)	Week 8 PASI 100	8.3 Percent of participant
AIN457150 mg- Induction Period Only(IPO)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Induction)	Week 2 PASI 90	0 Percent of participant
AIN457150 mg- Induction Period Only(IPO)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Induction)	Week 12 PASI 75	84.4 Percent of participant
AIN457150 mg- Induction Period Only(IPO)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Induction)	Week 2 PASI 100	0 Percent of participant
AIN457150 mg- Induction Period Only(IPO)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Induction)	Week 12 PASI 50	93.1 Percent of participant
AIN457150 mg- Induction Period Only(IPO)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Induction)	Week 4 IGA 0/1	15.6 Percent of participant
AIN457150 mg- Induction Period Only(IPO)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Induction)	Week 12 PASI 90	49.3 Percent of participant
AIN457150 mg- Induction Period Only(IPO)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Induction)	Week 4 PASI 75	27.9 Percent of participant
AIN457150 mg- Induction Period Only(IPO)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Induction)	Week 12 PASI 100	16.2 Percent of participant
AIN457150 mg- Induction Period Only(IPO)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Induction)	Week 2 IGA 0/1	1.2 Percent of participant
AIN457 300 mg - IPO	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Induction)	Week 12 PASI 100	25.7 Percent of participant
AIN457 300 mg - IPO	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Induction)	Week 2 IGA 0/1	3.1 Percent of participant
AIN457 300 mg - IPO	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Induction)	Week 2 PASI 90	0.2 Percent of participant
AIN457 300 mg - IPO	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Induction)	Week 3 PASI 50	63.6 Percent of participant
AIN457 300 mg - IPO	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Induction)	Week 3 PASI 90	3.1 Percent of participant
AIN457 300 mg - IPO	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Induction)	Week 4 PASI 50	81.8 Percent of participant
AIN457 300 mg - IPO	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Induction)	Week 4 PASI 90	13.7 Percent of participant
AIN457 300 mg - IPO	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Induction)	Week 8 PASI 100	13.9 Percent of participant
AIN457 300 mg - IPO	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Induction)	Week 2 PASI 75	5.2 Percent of participant
AIN457 300 mg - IPO	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Induction)	Week 2 PASI 50	32.9 Percent of participant
AIN457 300 mg - IPO	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Induction)	Week 2 PASI 100	0.2 Percent of participant
AIN457 300 mg - IPO	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Induction)	Week 3 IGA 0/1	9.3 Percent of participant
AIN457 300 mg - IPO	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Induction)	Week 3 PASI 75	19.3 Percent of participant
AIN457 300 mg - IPO	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Induction)	Week 3 PASI 100	0.6 Percent of participant
AIN457 300 mg - IPO	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Induction)	Week 4 IGA 0/1	25.5 Percent of participant
AIN457 300 mg - IPO	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Induction)	Week 4 PASI 75	42.9 Percent of participant
AIN457 300 mg - IPO	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Induction)	Week 4 PASI 100	2.3 Percent of participant
AIN457 300 mg - IPO	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Induction)	Week 8 IGA 0/1	59.4 Percent of participant
AIN457 300 mg - IPO	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Induction)	Week 8 PASI 75	76.8 Percent of participant
AIN457 300 mg - IPO	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Induction)	Week 8 PASI 50	93 Percent of participant
AIN457 300 mg - IPO	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Induction)	Week 8 PASI 90	45.8 Percent of participant
AIN457 300 mg - IPO	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Induction)	Week 12 IGA 0/1	76 Percent of participant
AIN457 300 mg - IPO	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Induction)	Week 12 PASI 75	90.1 Percent of participant
AIN457 300 mg - IPO	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Induction)	Week 12 PASI 50	96.1 Percent of participant
AIN457 300 mg - IPO	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Induction)	Week 12 PASI 90	64.2 Percent of participant

Secondary

Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))

The IGA mod 2011 is a static scale, i.e., it refers exclusively to the participant's disease state at the time of the assessments and does not attempt a comparison to any of the participant's previous disease states at prior visits. The score ranges from 0 (clear) to 4 (severe. The score 0 is clear, 1 is almost clear, 2 is mild, 3 is moderate, and 4 is severe

Time frame: Baseline, week 16,20,24,28,32,36,40,44,48, and Week 52

Population: Full analysis set (FAS) - All patients to whom study treatment was assigned

Arm	Measure	Group	Value (NUMBER)
AIN457 150 mg - Fixed Interval (FI)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 48 PASI 100	21.2 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 20 PASI 90	62.6 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 40 PASI 50	87.7 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 20 PASI 100	29.1 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 36 PASI 90	54.7 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 16 PASI 90	59.1 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 48 PASI 90	49.8 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 24 IGA 0/1	67.5 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 40 PASI 75	68 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 48 IGA 0/1	51.7 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 36 PASI 100	28.6 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 24 PASI 75	80.3 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 52 PASI 50	83.7 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 40 PASI 100	26.1 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 48 PASI 50	83.3 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 24 PASI 50	93.1 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 40 PASI 90	52.2 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 52 PASI 90	45.8 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 40 IGA 0/1	53.2 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 24 PASI 90	66.5 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 36 PASI 75	71.4 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 48 PASI 75	65.5 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 52 PASI 75	62.1 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 24 PASI 100	29.1 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 16 PASI 100	27.6 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 32 PASI 100	30.5 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 44 PASI 90	49.8 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 28 IGA 0/1	65.5 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 16 PASI 75	90.1 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 32 PASI 90	58.6 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 20 IGA 0/1	69 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 28 PASI 75	77.3 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 16 PASI 50	96.1 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 52 PASI 100	21.2 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 44 PASI 50	84.2 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 28 PASI 50	92.6 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 52 IGA 0/1	47.3 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 16 IGA 0/1	70.9 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 20 PASI 75	85.7 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 28 PASI 90	60.6 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 36 PASI 50	87.7 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 44 PASI 100	22.7 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 44 PASI 75	66 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 28 PASI 100	29.6 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 32 PASI 75	74.9 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 20 PASI 50	94.6 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 36 IGA 0/1	59.6 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 32 IGA 0/1	64 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 32 PASI 50	91.1 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 44 IGA 0/1	52.7 Percent of participants
AIN457 300 mg FI	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 16 PASI 75	92.1 Percent of participants
AIN457 300 mg FI	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 32 PASI 75	84.3 Percent of participants
AIN457 300 mg FI	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 52 PASI 100	36.6 Percent of participants
AIN457 300 mg FI	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 40 PASI 100	38 Percent of participants
AIN457 300 mg FI	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 32 PASI 90	74.1 Percent of participants
AIN457 300 mg FI	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 32 PASI 100	38.9 Percent of participants
AIN457 300 mg FI	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 40 PASI 90	68.5 Percent of participants
AIN457 300 mg FI	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 36 IGA 0/1	70.4 Percent of participants
AIN457 300 mg FI	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 16 PASI 50	97.7 Percent of participants
AIN457 300 mg FI	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 36 PASI 75	82.9 Percent of participants
AIN457 300 mg FI	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 36 PASI 90	68.1 Percent of participants
AIN457 300 mg FI	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 40 PASI 50	90.7 Percent of participants
AIN457 300 mg FI	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 36 PASI 50	91.2 Percent of participants
AIN457 300 mg FI	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 52 PASI 75	78.2 Percent of participants
AIN457 300 mg FI	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 36 PASI 100	38.9 Percent of participants
AIN457 300 mg FI	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 16 PASI 90	75.5 Percent of participants
AIN457 300 mg FI	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 40 IGA 0/1	68.5 Percent of participants
AIN457 300 mg FI	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 40 PASI 75	81.5 Percent of participants
AIN457 300 mg FI	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 16 PASI 100	31.5 Percent of participants
AIN457 300 mg FI	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 52 IGA 0/1	59.3 Percent of participants
AIN457 300 mg FI	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 20 IGA 0/1	75.5 Percent of participants
AIN457 300 mg FI	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 20 PASI 75	90.3 Percent of participants
AIN457 300 mg FI	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 48 PASI 100	38.4 Percent of participants
AIN457 300 mg FI	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 20 PASI 50	97.7 Percent of participants
AIN457 300 mg FI	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 48 PASI 90	62.5 Percent of participants
AIN457 300 mg FI	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 20 PASI 100	35.6 Percent of participants
AIN457 300 mg FI	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 52 PASI 90	59.7 Percent of participants
AIN457 300 mg FI	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 24 IGA 0/1	76.9 Percent of participants
AIN457 300 mg FI	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 48 PASI 50	89.8 Percent of participants
AIN457 300 mg FI	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 24 PASI 75	88 Percent of participants
AIN457 300 mg FI	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 48 IGA 0/1	64.8 Percent of participants
AIN457 300 mg FI	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 24 PASI 50	94.9 Percent of participants
AIN457 300 mg FI	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 48 PASI 75	78.7 Percent of participants
AIN457 300 mg FI	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 24 PASI 90	74.1 Percent of participants
AIN457 300 mg FI	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 44 PASI 100	39.8 Percent of participants
AIN457 300 mg FI	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 24 PASI 100	36.1 Percent of participants
AIN457 300 mg FI	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 44 PASI 90	66.2 Percent of participants
AIN457 300 mg FI	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 28 IGA 0/1	72.7 Percent of participants
AIN457 300 mg FI	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 32 PASI 50	92.6 Percent of participants
AIN457 300 mg FI	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 44 PASI 50	92.1 Percent of participants
AIN457 300 mg FI	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 28 PASI 75	85.6 Percent of participants
AIN457 300 mg FI	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 52 PASI 50	87.5 Percent of participants
AIN457 300 mg FI	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 28 PASI 50	93.5 Percent of participants
AIN457 300 mg FI	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 44 PASI 75	80.1 Percent of participants
AIN457 300 mg FI	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 28 PASI 90	70.4 Percent of participants
AIN457 300 mg FI	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 16 IGA 0/1	82.4 Percent of participants
AIN457 300 mg FI	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 28 PASI 100	38 Percent of participants
AIN457 300 mg FI	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 20 PASI 90	74.5 Percent of participants
AIN457 300 mg FI	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 44 IGA 0/1	64.8 Percent of participants
AIN457 300 mg FI	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 32 IGA 0/1	74.1 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 24 PASI 100	19.9 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 20 PASI 90	55.8 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 32 PASI 50	82 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 40 PASI 75	42.2 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 44 PASI 100	1.5 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 52 PASI 100	2.4 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 16 IGA 0/1	74.8 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 16 PASI 75	92.7 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 16 PASI 50	98.1 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 16 PASI 90	68.4 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 16 PASI 100	22.3 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 20 IGA 0/1	64.6 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 20 PASI 75	81.6 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 20 PASI 50	92.2 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 20 PASI 100	24.8 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 24 IGA 0/1	56.3 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 24 PASI 75	72.3 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 24 PASI 50	89.3 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 24 PASI 90	51.5 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 28 IGA 0/1	44.7 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 28 PASI 75	65 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 28 PASI 50	87.4 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 28 PASI 90	40.8 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 28 PASI 100	15.5 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 32 IGA 0/1	33.5 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 32 PASI 75	50.5 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 32 PASI 90	32.5 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 32 PASI 100	10.7 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 36 IGA 0/1	27.2 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 36 PASI 75	45.1 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 36 PASI 50	78.6 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 36 PASI 90	24.8 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 36 PASI 100	2.9 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 40 IGA 0/1	26.2 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 40 PASI 50	74.8 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 40 PASI 90	18.9 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 40 PASI 100	1.9 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 44 IGA 0/1	20.4 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 44 PASI 75	37.4 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 44 PASI 50	72.8 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 44 PASI 90	16.5 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 48 IGA 0/1	20.4 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 48 PASI 75	33 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 48 PASI 50	74.8 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 48 PASI 90	12.6 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 48 PASI 100	1 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 52 IGA 0/1	18 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 52 PASI 75	35 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 52 PASI 50	73.8 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 52 PASI 90	11.2 Percent of participants
AIN457 300 mg- SoR	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 32 IGA 0/1	46.1 Percent of participants
AIN457 300 mg- SoR	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 28 PASI 100	23 Percent of participants
AIN457 300 mg- SoR	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 16 PASI 50	98.2 Percent of participants
AIN457 300 mg- SoR	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 44 IGA 0/1	27.6 Percent of participants
AIN457 300 mg- SoR	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 28 PASI 90	50.2 Percent of participants
AIN457 300 mg- SoR	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 28 PASI 50	94 Percent of participants
AIN457 300 mg- SoR	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 52 PASI 90	13.8 Percent of participants
AIN457 300 mg- SoR	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 44 PASI 75	51.2 Percent of participants
AIN457 300 mg- SoR	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 28 PASI 75	71.4 Percent of participants
AIN457 300 mg- SoR	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 28 IGA 0/1	52.5 Percent of participants
AIN457 300 mg- SoR	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 52 PASI 75	41 Percent of participants
AIN457 300 mg- SoR	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 44 PASI 50	82.5 Percent of participants
AIN457 300 mg- SoR	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 24 PASI 100	26.3 Percent of participants
AIN457 300 mg- SoR	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 16 IGA 0/1	83.4 Percent of participants
AIN457 300 mg- SoR	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 16 PASI 75	94.9 Percent of participants
AIN457 300 mg- SoR	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 24 PASI 90	59.9 Percent of participants
AIN457 300 mg- SoR	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 52 PASI 100	5.1 Percent of participants
AIN457 300 mg- SoR	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 24 PASI 50	94 Percent of participants
AIN457 300 mg- SoR	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 44 PASI 90	22.1 Percent of participants
AIN457 300 mg- SoR	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 48 PASI 75	45.6 Percent of participants
AIN457 300 mg- SoR	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 24 PASI 75	77.9 Percent of participants
AIN457 300 mg- SoR	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 24 IGA 0/1	65.9 Percent of participants
AIN457 300 mg- SoR	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 52 PASI 50	81.1 Percent of participants
AIN457 300 mg- SoR	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 48 PASI 50	82 Percent of participants
AIN457 300 mg- SoR	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 20 PASI 100	35.5 Percent of participants
AIN457 300 mg- SoR	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 20 PASI 90	72.8 Percent of participants
AIN457 300 mg- SoR	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 48 IGA 0/1	21.7 Percent of participants
AIN457 300 mg- SoR	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 48 PASI 90	14.7 Percent of participants
AIN457 300 mg- SoR	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 20 PASI 50	97.2 Percent of participants
AIN457 300 mg- SoR	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 20 PASI 75	87.1 Percent of participants
AIN457 300 mg- SoR	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 44 PASI 100	4.6 Percent of participants
AIN457 300 mg- SoR	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 48 PASI 100	3.7 Percent of participants
AIN457 300 mg- SoR	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 20 IGA 0/1	77 Percent of participants
AIN457 300 mg- SoR	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 36 PASI 100	7.4 Percent of participants
AIN457 300 mg- SoR	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 16 PASI 100	38.2 Percent of participants
AIN457 300 mg- SoR	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 40 IGA 0/1	35.5 Percent of participants
AIN457 300 mg- SoR	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 36 PASI 90	35.5 Percent of participants
AIN457 300 mg- SoR	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 40 PASI 75	58.5 Percent of participants
AIN457 300 mg- SoR	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 36 PASI 50	94 Percent of participants
AIN457 300 mg- SoR	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 36 PASI 75	58.1 Percent of participants
AIN457 300 mg- SoR	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 32 PASI 50	90.3 Percent of participants
AIN457 300 mg- SoR	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 40 PASI 50	88.9 Percent of participants
AIN457 300 mg- SoR	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 36 IGA 0/1	33.6 Percent of participants
AIN457 300 mg- SoR	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 32 PASI 100	15.7 Percent of participants
AIN457 300 mg- SoR	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 52 IGA 0/1	20.3 Percent of participants
AIN457 300 mg- SoR	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 40 PASI 90	26.7 Percent of participants
AIN457 300 mg- SoR	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 32 PASI 90	41.5 Percent of participants
AIN457 300 mg- SoR	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 32 PASI 75	63.1 Percent of participants
AIN457 300 mg- SoR	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 16 PASI 90	76.5 Percent of participants
AIN457 300 mg- SoR	Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))	Week 40 PASI 100	7.4 Percent of participants

Secondary

Percent of Responders With PASI Equal to or Greater Than 50, PASI 75, PASI 90, PASI 100 and Percent of Responders With IGA Score of 0 or 1 Who Failed to Respond to a Previous Biologic Psoriasis Therapy

Time frame: Week 52

Population: Full analysis set (FAS) - All patients to whom study treatment was assigned, only participants with evaluable data were included

Arm	Measure	Group	Value (NUMBER)
AIN457 150 mg - Fixed Interval (FI)	Percent of Responders With PASI Equal to or Greater Than 50, PASI 75, PASI 90, PASI 100 and Percent of Responders With IGA Score of 0 or 1 Who Failed to Respond to a Previous Biologic Psoriasis Therapy	Week 52 PASI 90	33.3 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Percent of Responders With PASI Equal to or Greater Than 50, PASI 75, PASI 90, PASI 100 and Percent of Responders With IGA Score of 0 or 1 Who Failed to Respond to a Previous Biologic Psoriasis Therapy	Week 52 PASI 50	81 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Percent of Responders With PASI Equal to or Greater Than 50, PASI 75, PASI 90, PASI 100 and Percent of Responders With IGA Score of 0 or 1 Who Failed to Respond to a Previous Biologic Psoriasis Therapy	Week 52 PASI 100	28.6 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Percent of Responders With PASI Equal to or Greater Than 50, PASI 75, PASI 90, PASI 100 and Percent of Responders With IGA Score of 0 or 1 Who Failed to Respond to a Previous Biologic Psoriasis Therapy	Week 52 PASI 75	47.6 Percent of participants
AIN457 150 mg - Fixed Interval (FI)	Percent of Responders With PASI Equal to or Greater Than 50, PASI 75, PASI 90, PASI 100 and Percent of Responders With IGA Score of 0 or 1 Who Failed to Respond to a Previous Biologic Psoriasis Therapy	Week 52 IGA 0/1	42.9 Percent of participants
AIN457 300 mg FI	Percent of Responders With PASI Equal to or Greater Than 50, PASI 75, PASI 90, PASI 100 and Percent of Responders With IGA Score of 0 or 1 Who Failed to Respond to a Previous Biologic Psoriasis Therapy	Week 52 PASI 75	77.8 Percent of participants
AIN457 300 mg FI	Percent of Responders With PASI Equal to or Greater Than 50, PASI 75, PASI 90, PASI 100 and Percent of Responders With IGA Score of 0 or 1 Who Failed to Respond to a Previous Biologic Psoriasis Therapy	Week 52 PASI 90	66.7 Percent of participants
AIN457 300 mg FI	Percent of Responders With PASI Equal to or Greater Than 50, PASI 75, PASI 90, PASI 100 and Percent of Responders With IGA Score of 0 or 1 Who Failed to Respond to a Previous Biologic Psoriasis Therapy	Week 52 PASI 100	52.8 Percent of participants
AIN457 300 mg FI	Percent of Responders With PASI Equal to or Greater Than 50, PASI 75, PASI 90, PASI 100 and Percent of Responders With IGA Score of 0 or 1 Who Failed to Respond to a Previous Biologic Psoriasis Therapy	Week 52 PASI 50	86.1 Percent of participants
AIN457 300 mg FI	Percent of Responders With PASI Equal to or Greater Than 50, PASI 75, PASI 90, PASI 100 and Percent of Responders With IGA Score of 0 or 1 Who Failed to Respond to a Previous Biologic Psoriasis Therapy	Week 52 IGA 0/1	66.7 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Percent of Responders With PASI Equal to or Greater Than 50, PASI 75, PASI 90, PASI 100 and Percent of Responders With IGA Score of 0 or 1 Who Failed to Respond to a Previous Biologic Psoriasis Therapy	Week 52 PASI 75	21.7 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Percent of Responders With PASI Equal to or Greater Than 50, PASI 75, PASI 90, PASI 100 and Percent of Responders With IGA Score of 0 or 1 Who Failed to Respond to a Previous Biologic Psoriasis Therapy	Week 52 IGA 0/1	4.3 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Percent of Responders With PASI Equal to or Greater Than 50, PASI 75, PASI 90, PASI 100 and Percent of Responders With IGA Score of 0 or 1 Who Failed to Respond to a Previous Biologic Psoriasis Therapy	Week 52 PASI 50	60.9 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Percent of Responders With PASI Equal to or Greater Than 50, PASI 75, PASI 90, PASI 100 and Percent of Responders With IGA Score of 0 or 1 Who Failed to Respond to a Previous Biologic Psoriasis Therapy	Week 52 PASI 90	13 Percent of participants
AIN457 150 mg- Start of Relapse (SoR)	Percent of Responders With PASI Equal to or Greater Than 50, PASI 75, PASI 90, PASI 100 and Percent of Responders With IGA Score of 0 or 1 Who Failed to Respond to a Previous Biologic Psoriasis Therapy	Week 52 PASI 100	0 Percent of participants
AIN457 300 mg- SoR	Percent of Responders With PASI Equal to or Greater Than 50, PASI 75, PASI 90, PASI 100 and Percent of Responders With IGA Score of 0 or 1 Who Failed to Respond to a Previous Biologic Psoriasis Therapy	Week 52 PASI 90	7.1 Percent of participants
AIN457 300 mg- SoR	Percent of Responders With PASI Equal to or Greater Than 50, PASI 75, PASI 90, PASI 100 and Percent of Responders With IGA Score of 0 or 1 Who Failed to Respond to a Previous Biologic Psoriasis Therapy	Week 52 PASI 50	75 Percent of participants
AIN457 300 mg- SoR	Percent of Responders With PASI Equal to or Greater Than 50, PASI 75, PASI 90, PASI 100 and Percent of Responders With IGA Score of 0 or 1 Who Failed to Respond to a Previous Biologic Psoriasis Therapy	Week 52 IGA 0/1	14.3 Percent of participants
AIN457 300 mg- SoR	Percent of Responders With PASI Equal to or Greater Than 50, PASI 75, PASI 90, PASI 100 and Percent of Responders With IGA Score of 0 or 1 Who Failed to Respond to a Previous Biologic Psoriasis Therapy	Week 52 PASI 75	32.1 Percent of participants
AIN457 300 mg- SoR	Percent of Responders With PASI Equal to or Greater Than 50, PASI 75, PASI 90, PASI 100 and Percent of Responders With IGA Score of 0 or 1 Who Failed to Respond to a Previous Biologic Psoriasis Therapy	Week 52 PASI 100	3.6 Percent of participants

Secondary

Percent of Responders With PASI Equal to or Greater Than 50, PASI 75, PASI 90, PASI 100 and Percent of Responders With IGA Score of 0 or 1 Who Failed to Respond to a Previous Biologic Psoriasis Therapy

Time frame: Week 12

Population: Full analysis set (FAS) - All patients to whom study treatment was assigned, only participants with evaluable data were included

Arm	Measure	Group	Value (NUMBER)
AIN457150 mg- Induction Period Only(IPO)	Percent of Responders With PASI Equal to or Greater Than 50, PASI 75, PASI 90, PASI 100 and Percent of Responders With IGA Score of 0 or 1 Who Failed to Respond to a Previous Biologic Psoriasis Therapy	Week 12 PASI 75	68.8 Percent of participants
AIN457150 mg- Induction Period Only(IPO)	Percent of Responders With PASI Equal to or Greater Than 50, PASI 75, PASI 90, PASI 100 and Percent of Responders With IGA Score of 0 or 1 Who Failed to Respond to a Previous Biologic Psoriasis Therapy	Week 12 PASI 90	26.6 Percent of participants
AIN457150 mg- Induction Period Only(IPO)	Percent of Responders With PASI Equal to or Greater Than 50, PASI 75, PASI 90, PASI 100 and Percent of Responders With IGA Score of 0 or 1 Who Failed to Respond to a Previous Biologic Psoriasis Therapy	Week 12 PASI 50	87.5 Percent of participants
AIN457150 mg- Induction Period Only(IPO)	Percent of Responders With PASI Equal to or Greater Than 50, PASI 75, PASI 90, PASI 100 and Percent of Responders With IGA Score of 0 or 1 Who Failed to Respond to a Previous Biologic Psoriasis Therapy	Week 12 PASI 100	6.3 Percent of participants
AIN457150 mg- Induction Period Only(IPO)	Percent of Responders With PASI Equal to or Greater Than 50, PASI 75, PASI 90, PASI 100 and Percent of Responders With IGA Score of 0 or 1 Who Failed to Respond to a Previous Biologic Psoriasis Therapy	Week 12 IGA 0/1	42.2 Percent of participants
AIN457 300 mg - IPO	Percent of Responders With PASI Equal to or Greater Than 50, PASI 75, PASI 90, PASI 100 and Percent of Responders With IGA Score of 0 or 1 Who Failed to Respond to a Previous Biologic Psoriasis Therapy	Week 12 PASI 100	21.6 Percent of participants
AIN457 300 mg - IPO	Percent of Responders With PASI Equal to or Greater Than 50, PASI 75, PASI 90, PASI 100 and Percent of Responders With IGA Score of 0 or 1 Who Failed to Respond to a Previous Biologic Psoriasis Therapy	Week 12 IGA 0/1	62.2 Percent of participants
AIN457 300 mg - IPO	Percent of Responders With PASI Equal to or Greater Than 50, PASI 75, PASI 90, PASI 100 and Percent of Responders With IGA Score of 0 or 1 Who Failed to Respond to a Previous Biologic Psoriasis Therapy	Week 12 PASI 50	90.5 Percent of participants
AIN457 300 mg - IPO	Percent of Responders With PASI Equal to or Greater Than 50, PASI 75, PASI 90, PASI 100 and Percent of Responders With IGA Score of 0 or 1 Who Failed to Respond to a Previous Biologic Psoriasis Therapy	Week 12 PASI 90	56.8 Percent of participants
AIN457 300 mg - IPO	Percent of Responders With PASI Equal to or Greater Than 50, PASI 75, PASI 90, PASI 100 and Percent of Responders With IGA Score of 0 or 1 Who Failed to Respond to a Previous Biologic Psoriasis Therapy	Week 12 PASI 75	86.5 Percent of participants

Source: ClinicalTrials.gov · Data processed: Mar 1, 2026

Efficacy and Safety of Subcutaneous Secukinumab (AIN457) for Moderate to Severe Chronic Plaque-type Psoriasis Assessing Different Doses and Dose Regimens

Conditions

Keywords

Brief summary

Related papers

Interventions

Sponsors

Study design

Eligibility

Inclusion criteria

Exclusion criteria

Design outcomes

Primary

Secondary

Countries

Participant flow

Recruitment details

Participants by arm

Withdrawals & dropouts

Baseline characteristics

Adverse events

Outcome results

For the Fixed Interval Group and the Start of Relapse (SoR) Group, the Percentage of Participants (Who Responded to Treatment at Week 12) Maintaining a 75% Improvement From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 52

Absolute Change From Baseline for PASI 50 / 75 / 90 / 100 and IGA 2011 Score of 0 or 1 at Week 2, 4, 6, 8, 12

Absolute Change From Baseline for PASI 50 / 75 / 90 / 100 and IGA 2011 Score of 0 or 1 at Week at Week 16, 20, 24,28,32,36,40,44,48,and Week 52

Change From Baseline in Dermatology Life Quality Index (DLQI) Score. up to Week 52, (Induction)

Change From Baseline in Dermatology Life Quality Index (DLQI) Score. up to Week 52, (Maintenance)

Change From Baseline in EQ-5D at Each Visit, up to Week 52, (Induction)

Change From Baseline in EQ-5D at Each Visit, up to Week 52, (Maintenance)

Median Time to Relapse (Weeks) From Week 12.

Number of Participants Developing Anti-secukinumab Antibodies

Number of Secukinumab Injections Needed to Regain PASI 75 Response From Start of Relapse After Week 12

Number of Visits With PASI 50, 75, 90, 100 Score and IGA Mod 2011 0 or 1

% of Participants Achieving a DLQI Score of 0 or 1 at Each Visit up to Week 52, (Induction)

% of Participants Achieving a DLQI Score of 0 or 1 at Each Visit up to Week 52, (Maintenance).

Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Induction)

Percent of Participants Achieving Psoriasis Area & Severity Index (PASI) Score and IGA Mod 2011 0 or 1 Score Over Time at Week 12 and 52 (Maintenance Period))

Percent of Responders With PASI Equal to or Greater Than 50, PASI 75, PASI 90, PASI 100 and Percent of Responders With IGA Score of 0 or 1 Who Failed to Respond to a Previous Biologic Psoriasis Therapy

Percent of Responders With PASI Equal to or Greater Than 50, PASI 75, PASI 90, PASI 100 and Percent of Responders With IGA Score of 0 or 1 Who Failed to Respond to a Previous Biologic Psoriasis Therapy